final program

Nice, France December 4 – 7, 2014

www.kenes.com/nmdpd

FINAL PROGRAM


www.kenes.com/nmdpd

FINAL PROGRAM

TABLE OF CONTENTS CONGRESS INFORMATION Welcoming Words

3

Committees

4

General Information

5

Networking Events

6

CME Accreditation

7

Information for Presenters

9

e-Poster Session Overview

10

Awards11 Venue Map

12

SCIENTIFIC PROGRAM Thursday, December 4, 2014

13

Friday, December 5, 2014

17

Saturday, December 6, 2014

29

Sunday, December 7, 2014

39

e-Poster Presentations

47

e-Posters51 Index of Authors

67

RECOGNITION, ACKNOWLEDGEMENTS AND INDUSTRY SUPPORT

2

Acknowledgements

81

Industry Organised Symposia

82

List of Exhibitors

84

Exhibitor and Supporter Profiles

85

Welcoming Words Dear Colleagues, Following the successful MDPD congress in Seoul, Korea, we are delighted to welcome you to the 10th International Congress on Non-Motor Dysfunctions in Parkinson’s disease and Related Disorders (now renamed NMDPD) in Nice, France on December 4-7, 2014. We hope that this Congress will be as much a success as our previous congresses. We are confident this congress will provide a splendid scientific program in an amazing environment. Our aim is to discuss the new developments in the understanding of the non-motor aspects of Parkinson’s disease and other movement disorders and their management. During this exciting Congress we shall have an opportunity to deliberate on brain diseases and how they contribute to cognition and behavior. We shall try to identify the psychological markers, if any, of Parkinson’s dementia and of dementia with Lewy bodies, and also the biochemical and genetic factors involved. The identification in recent years of widespread alpha-synuclein deposits, from the periphery and up to the cortex, has contributed to our understanding but at the same time raised new and still unanswered questions. The overlap with Alzheimer’s disease and with fronto-temporal dementia will be another central issue, as will be the neurochemical changes seen in these disorders. Delirium, dementia, anxiety, psychosis and impulse control disorders frequently affect the lives of patients and caregivers even more than motor disturbances, and they therefore deserve special attention. Besides cognitive impairment, patients with movement disorders frequently complain of disturbances of the autonomic nervous system, REM sleep behavior disorder, and hyposmia, to name just a few. All these aspects which will be discussed in detail. Nice, on the beautiful French Riviera, will provide a wonderful opportunity to exchange ideas and presentation of new research findings. We hope that you will benefit greatly from your participation in the stimulating scientific sessions as well as enjoy the special charm of Nice. Welcome to Nice! Yours Sincerely, Congress Chairmen

Amos D. Korczyn

Heinz Reichmann

Ray Chaudhury

3

Committees HONORARY PRESIDENT

CONGRESS CHAIRMEN K Ray Chaudhuri, UK Amos D. Korczyn, Israel Heinz Reichmann, Germany

Yves Agid, France

INTERNATIONAL ADVISORY BOARD Dag Aarsland, Norway Roy Alcalay, USA Angelo Antonini, Italy Stavros Baloyannis, Greece Paolo Barone, Italy Kemal Bayulkem, Turkey Madhuri Behari, India Jon Beom, Korea Kalyan Bhattacharyya, India Roongroj Bhidayasiri, Thailand Bass Bloem, The Netherlands David Brooks, UK David Burn, UK Pasquale Calabrese, Switzerland Piu Chan, China K.Ray Chaudhuri, UK Shengdi Chen, China Marie Francoise Chesselet, USA Dirk Dressler, Germany John Duda, USA Muret Emre, Turkey Stanley Fahn, USA Andrej Friedman, Poland Thomas Gasser, Germany David Goldstein, USA Nir Giladi, Israel Lea Grinberg, USA Alla Guekht, Russia

LOCAL ADVISORY BOARD Jean-Philipe Azulay Michel Borg Alexis Brice Emmanuel Broussolle Stephan Chabardes Henri Cohen Philippe Damier 4

Nobu Hattori, Japan Shu-Leong Ho, Hong-Kong Jonas Hon Ming Yeung , Hong-Kong Unjoong Kang, USA Vladimir Kostic, Serbia Jaime Kulisevsky, Spain Jan-Peter Larsen, Norway Wei-Dong Le, USA Irene Litvan , USA Ching-Song Lu, Taiwan Iddo Magen, Israel/USA Margarita Makoutonina, Australia Silvia Mandel, Israel Pablo Martinez-Martin, Spain Eliezer Masliah, USA Chris Mathias, UK Ian McKeith, UK Park Mee Y, South Korea Vincent Mok, Hong-Kong Ouri Monchi, Canada Uday Muthane, India Per Odin, Sweden Aleksandra M. Pavlovic, Serbia Ron Pfeiffer, USA Zvezdan Pirtosek, Slovenia Werner Poewe, Austria Emmanuelle Pourcher, Canada Rivka Ravid, The Netherlands

Ivan Rektor, Czech Republic Irena Rektorova, Czech Republic Maja Relja, Croatia Nikolaos Robakis, USA Raymond Rosales, Philippines Evzen Ruzicka, Czech Republic Mike Samuel, UK Anthony Schapira, UK Michael Okun, USA Mark Stacy, USA Fabrizio Stocchi, Italy Jon Stoessl, British Colombia Pille Taba, Estonia Ryosuke Takahashi, Japan Atsushi Takeda, Japan Eng-King Tan , Singapore Michele Tinazzi, Italy Zlatko Trkanjec, Croatia Daniel D. Truong, USA Magda Tsolaki , Greece Laszlo Vecsei, Hungary Richard Walker, UK Zuzana Walker,UK Daniel Weintraub, USA Erik Wolters , The Netherlands Ruey-Meei Wu, Taiwan Mitsutoshi Yamamoto, Japan Moussa Youdim, Israel

Alain Destée Bruno Dubois Charles Duyckaerts Alexis Elbaz Anne-Marie Ergis Caroline Giordana Etienne Hirsch

Benoit Kullman Paul Krack Oliver Rascol Stephane Thobois Marie Vidailhet

GENERAL INFORMATION CONGRESS VENUE

Nice Acropolis Esplanade Kennedy - BP4083 - 06302 Nice cedex 4 - France

LANGUAGE

English is the official language of the Congress.

hours

Thursday, December 4, 2014 Friday, December 5, 2014 Saturday, December 6, 2014 Sunday, December 7, 2014

REGISTRATION DESK 13:30-19:00 06:30-18:00 07:00-18:15 07:00-13:00

EXHIBITION 17:00-20:30 09:30-16:30 09:30-16:30 09:30-13:00

PARTICIPANTS BADGE

Upon registration, you will receive your name badge. You are kindly requested to wear your name badge to be permitted access to Congress sessions and events.

INTERNET STATIONS

Free internet stations with email facilities will be available in the exhibition area during the exhibition opening hours only. Please be considerate of fellow participants when using these facilities.

REFRESHMENTS

Coffee will be served in the Exhibition area at the times indicated in the Scientific Program.

PHOTOGRAPHY AND RECORDING PRIVILEGES

No photographs, video recording or audio recording may be permitted in the scientific sessions at this Congress unless otherwise authorized by the Scientific Committee or the Congress Chairman.

SAFETY AND SECURITY

Please do not leave any bags or suitcases unattended at any time, whether inside or outside session halls.

SMOKING POLICY

Participants are kindly requested to refrain from smoking at the congress venue.

EMERGENCY TELEPHONE NUMBERS

Fire department, Police and Ambulance services are available via telephone number 112

5

LIABILITY

The registration fees do not include the insurance of participants against personal accidents, sickness, and cancellations by any party, theft, loss or damage to personal possessions. Participants are advised to take out adequate personal insurance to cover travel, accommodation, cancellation and personal effects.

RECOGNITION, ACKNOWLEDGEMENTS AND INDUSTRY SUPPORT In accordance with compliance regulations, Industry supporting the congress will be acknowledged separately from the Scientific Program. Industry Information will appear at the back of the book, under the section RECOGNITION, ACKNOWLEDGEMENTS AND INDUSTRY SUPPORT.

GUEST ATTENDANCE POLICY

All event activities (including educational sessions, meal functions, exhibit hall, etc.) are exclusively reserved for registered attendees. Non-registered guests (including children, family members, colleagues, etc.) are not allowed in any of the event areas. Badges provided at registration are required for entrance into all functions and will be strictly enforced.

CONGRESS SECRETARIAT

Rue François-Versonnex 7 1207 Geneva, Switzerland Website: [email protected]

NETWORKING EVENTS Opening Ceremony and Welcome Reception Thursday, December 4, 2014 The official opening ceremony will take place on December 4, 2014 at 16:30-17:00, followed by the Plenary Session. After the plenary session, all participants are invited to join us at 19:00 for a Welcome Reception in the exhibition area.

6

CME ACCREDITATION COMMITMENT TO THE HIGHEST STANDARDS IN CME/CPD

Kenes is committed to being a valuable and knowledgeable partner in the design and delivery of educationally strong, independent, transparent, and effective CME/CPD programmes. Kenes is a proud member of the Good CME Practice Group (gCMEp), a member organization contributing to improving health outcomes by: Championing best practice in CME Maintaining and improving standards Mentoring and educating Working in collaboration with critical stakeholders

EDUCATIONAL OBJECTIVES

After attending this event, participants should be able to: • Address individual needs in compliance with their Continuous Professional Development (CPD) plan • Discuss how current developments in the area of movement disorders with special attention to cognition, behavior, sensory and autonomic dysfunction • Debate on molecular changes in movement disorders and related brain diseases and how they contribute to cognitive decline and behavioral changes • Identify specific biological and psychological markers of dementia and the genetic factors involved • Determine the overlap of Lewy body dementia with Alzheimer’s disease • Recognize the neuropathological and imaging features of cognitive changes in movement disorders • Enhance dialogue between clinicians and researchers in the field of vascular dementia as a means of further developing individual expertise • Apply behavioural and pharmacological steps in order to reduce the burden and improve quality of life of affected individuals and their families • Describe the underlying anatomical changes, and their reflections in neuroimaging studies and possibility to prognosticate future developments

TARGET AUDIENCE

NMDPD 2014 is the global meeting place for Physicians and Researchers in the field of Parkinson and other neurodegenerative diseases. Because of the diverse, clinically focused educational offering, participants are able to tailor the curriculum to meet the needs of international clinicians of all levels of experience.

ACCREDITATION STATEMENT AND CREDIT DESIGNATION

The 10th International Congress on Non-Motor Dysfunctions in Parkinson’s Disease and Related Disorders (NMDPD 2014) is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net. The 10th International Congress on Non-Motor Dysfunctions in Parkinson’s Disease and Related Disorders (NMDPD 2014) is designated for a maximum of, or up to, 15 European external CME credits of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. 7

American Medical Association (AMA)

Through an agreement between European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credit™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/internationalcmeEACCME credits are recognized by the American Medical Association towards the Physician’s Recognition Award (PRA).

The Royal College of Physicians and Surgeons of Canada

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification programme of The Royal College of Physicians and Surgeons of Canada. For more information, visit: www.royalcollege.ca

CREDIT BREAKDOWN

Each participant should claim only the hours of credit that he/she actually spent in the educational activity. Day

Maximum Credits

Thursday, December 4, 2014

2


4


6


3

Total Credits:

15

TO RECEIVE YOUR CME/CPD CERTIFICATE

The CME/CPD certificate will be available after completing the online evaluation and credit claiming procedure. The process takes about 5 minutes. We thank you for your feedback as it is an important part of CME/CPD accreditation and helps improve future educational offerings. Before January 4, 2015: 1. Access the online system via any of the following - Visit the following link: https://www.surveymonkey.com/s/NMDPD2014Evaluation - Visit the CME/CPD Accreditation page on the event website - Follow the link in the email sent at the end of the event 2. Complete the anonymous online evaluation 3. Complete the credit claim form and submit 4. The CME/CPD certificate will be available for download; fill-in and retain for your personal records

DISCLOSURE AND RESOLUTION OF PERSONAL CONFLICTS OF INTEREST

In accordance with CME/CPD accreditation criteria and standards for commercial support to ensure balance, independence, objectivity, and scientific rigor, those in control of the educational content must disclose potential or actual conflicts of interest. Disclosure information is evaluated and conflicts of interest resolved. Disclosure is made to participants prior to the activity. Participants will be asked on the evaluation to assess the objectivity and independence of the event. 8

INFORMATION FOR PRESENTERS ORAL PRESENTATIONS Data presentation:

If using a PowerPoint presentation ( or any other PC based application ), please note you need to bring it on USB Memory stick or CD/DVD and load it on one of the conference’ computers in the Speakers’ Ready Room at least 1 hour before the start of the session. Please note that the conference computers in the session halls are being supplied with Office 2010 ( at least ). If combining video films with PowerPoint, please make sure to check it in the session hall where your lecture is taking place during a coffee or lunch break prior to your session, at least 30 minutes before the start of the session - even after checking it in the Speakers’ Ready Room. Alternatively you may supply your own laptop computer. In such a case please confirm that it has a VGA socket for external signal and come to check it first in the Speakers’ Ready Room as soon as you arrive and later on in the session hall where your lecture is taking place during the coffee or lunch break prior to your session, at least 30 minutes before the start of the session.

Important note for Macintosh users

In order to use MAC presentations on a PC compatible computer please note that you need to prepare it according to the instructions below, before bringing it to the Speakers' Ready Room: 1. Use a common font, such as Arial, Times New Roman, Verdana etc. (special fonts might be changed to a default font on a PowerPoint based PC). 2. Insert pictures as JPG files (and not TIF, PNG or PICT - these images will not be visible on a PowerPoint based PC. Alternatively you may use your own Macintosh laptop computer. In such a case please confirm you provide it with a VGA adaptor for external signal, advise the operators in the Speakers’ Ready Room about it as soon as you arrive and later on test it in the session hall where your lecture is taking place during the coffee or lunch break prior to your session, at least 30 minutes before the start of the session.

9

e-POSTERS Experience a new kind of poster! The 10th International Congress on Non-Motor Dysfunctions in Parkinson’s Disease and Related Disorders is proud to implement an advanced electronic poster ‘e-poster’ format. The e-Poster terminals are located in the exhibition area of the conference centre. The e-Posters will be on display from December 5, 2014, 09:30 – December 7, 2014, 13:00. • All Posters will appear on plasma stations in the Poster Area in the Exhibition hall and are available for electronic viewing at all times for participants during the exhibition opening hours. • These posters do not require printing or production of materials – as the poster will be presented electronically. • This new format replaces the traditional paper poster board format • Viewers will be able to easily find and browse e-Posters and even download the e-Posters in PDF format when permitted by the presenter. With the new features, authors are not required to stand beside the e-poster terminals. • When the author has permitted, you will be able to use the e-mailing function to send a copy of the poster to yourself during the congress and option to contact a poster author via Das Terminal. This is a great way to ask for a meeting on site and talk about the research face to face.

e- POSTER PRESENTATIONS - SESSION OVERVIEW All e-posters presentations will be presented on the e-Poster terminals in the exhibition area. A select number of e-posters have been selected for short discussion, led by session chairpersons. The e-posters will be presented on the e-poster terminals in the exhibition hall. Each presenter will have 5 minutes to present. Please refer to the section for e-Poster presentations in the program book for details. Presenting authors are requested to arrive at least 5 minutes before the start of their session. e-Poster presentation

10

Date

Time

Chairpersons

NMS (Non-motor symptoms in PD)

Friday, December 5

10:00-10:30

Michael Borg, France Emmanuel Brousolle, France

QoL (Quality of life in PD)

Friday, December 5

16:00-16:30

Abdelhamid Benazzouz, France Stephane Thobois, France

Deep Brain Stimulation

Saturday, December 6

10:00-10:30

Franck Durif, France Anna Negrotti, Italy

Cognitive Dysfunction 1

Saturday, December 6

16:00-16:30

TBA Elka Stefanova, Serbia

Cognitive Dysfunction 2

Sunday, December 7

10:30-11:00

TBA Tanya Gurevich, Israel

Best e-Poster Award NMDPD 2014 will give prizes to the best e-posters presented at the Congress All accepted and presented e-posters will automatically be considered for the BEST e-POSTER AWARDS. e-Posters will be selected each day for a best poster prize. Prizes will include: •1 year subscription to the Lancet Neurology

•1 year online subscription to Parkinsonism and Related Disorders

•Copies of the book 'Clinical Recovery from CNS Damage' (2013)

The winners will be announced during the Closing Ceremony on Sunday, December 7 at 12:30-13:00.

11

VENUE MAP level 2

Exhibition, e-Posters

Risso 7

Risso 6

Athena Auditorium

Registration

Maia

12

Speakers' Ready Room

Hermes

Auditorium

Hermes Lounge

Thursday, December 4, 2014

www.kenes.com/nmdpd

scientific progra


O n

t h e

t h e r a p y o f

P a r k i n s o n ’ s M o v i n g

f o r w a r d

b y

d i s e a s e l o o k i n g

b a c k

The medical historical exhibition on Parkinson´s disease (PD) presents and honours major contributions in research and therapy which led to our today´s knowledge of PD and to the development of current treatment options. Milestones of this exiting history are identified and – wherever possible – linked to researchers and developers behind these advances. Starting with the seminal contribution of James Parkinson, this exhibition features early scientific contributions from Paris, Vienna and Berlin and retraces the quest for L-Dopa and other therapeutic agents. The last part of this exhibition is devoted to a look at more recent developments and future challenges in research and therapy.

Scientific Program Thursday, December 4, 2014

Presentation No.

Scientific Program Thursday, December 4, 2014 15:00 - 16:30

Hermes

Special Session: Video Session: The French Movement Disorder Society (CMA)

16:30 - 17:00

Athena

Plenary: Opening Ceremony

Chair: A. Korczyn (Israel)

1

Chair: Y. Agid (France)

2

WELCOME WORDS

3

Y. Agid (France)

WELCOME WORDS

4

A. Korczyn (Israel)

WELCOME WORDS

5

M. Gonce (France)

WELCOME WORDS

6

J. Azulay (France)

WELCOME WORDS

7

A. Antonini (Italy)

15

Thursday, December 4, 2014 Scientific Program

Presentation No.

17:00 - 19:00

Athena

Plenary session 1

17:00

Chair: V. Kostic (Serbia)

8

Chair: I. Rektorova (Czech Republic)

9

THE ROLE OF THE BASAL GANGLIA IN SUBCONSCIOUSNESS

10

Y. Agid (France) 17:40

HISTORY OF PSYCHIC NON MOTOR SIGNS IN PD FROM THE 19TH CENTURY

11

E. Brousolle (France) 18:20

DOES PD START IN THE GUT?

12

H. Reichmann, F. Pan-Montojo (Germany)

19:00 Networking Reception

16

Exhibition Area


www.kenes.com/nmdpd

scientific progra


THE

fb.com/theEPDA twitter.com/euparkinsons

EPDA

IMPROVING LIVES FOR PEOPLE WITH PARKINSON’S AND THEIR FAMILIES AND ADVOCATING FOR THE RIGHT TREATMENT AT THE RIGHT TIME www.epda.eu.com

The voice for Parkinson’s in Europe

Scientific Program friday, December 5, 2014

Presentation No.

Scientific Program Friday, December 5, 2014 7:00 - 8:30

Athena

inaugural trainees symposium: Session 1

7:00

Chair: S. Chabardes (France)

13

Chair: M.Y. Park (Korea)

14

COMPARISONS BETWEEN LEWY BODY DEMENTIA SYNDROMES AND DEMENTIA DUE TO ALZHEIMER'S DISEASE15 F.F. Oliveira, F.C. Machado, G. Sampaio, J.R. Wajman, S.M.C. Marin, P.H.F. Bertolucci (Brazil)

7:15

LEARNING NEEDS OF NON-MOVEMENT DISORDER SPECIALIST TEAMS MANAGING PD

16

S. Gangadharan, A. Withanage, M. Rees, C. Padmakumar (Australia) 7:30

LEVES OF CSF BIOMARKERS TAU, PHOSPHO-TAU, AB42 AND A-SYNUCLEIN IN PATIENTS WITH PARKINSONISM17 A. Bougea, G. Paraskevas, V.C. Konstantinides, V. Karagiorga, M. Bourbouli, E. Emmanouilidou, C. Vekrelis, E. Kapaki (Greece)

7:45

THE DUTCH PARKINSON AND COGNITION STUDY (DUPARC): ABOUT COGNITIVE PATHOLOGY IN DE NOVO PD PATIENTS, PROGRESSION AND EARLY INTERVENTION

18

S. Van der Zee, M.J.J. Gerritsen, J.M. Spikman, P.P. De Deyn, R.A. Dierckx, P.H. Elsinga, B.M. De Jong, S.K. Meles, T. Van Laar (Netherlands) 8:00

THE PERSONALITY FACTOR ‘OPENNESS TO EXPERIENCE’ AND EXECUTIVE FUNCTIONS IN PATIENTS WITH PD 19 R. Zimmermann, U. Gschwandtner, A. Meyer, D. Wiesli, P. Fuhr (Switzerland)

8:15

VALIDATION OF APATHY/MOOD DOMAIN (SCALE FOR EVALUATION OF THE NEUROPSYCHIATRIC DISORDERS IN PD - SEND-PD) WITH THE APATHY EVALUATION SCALE (AESS, AES-C)

20

A. Meyer, R. Zimmermann, U. Gschwandtner, R.D. Stieglitz, P. Fuhr (Switzerland)

19

friday, December 5, 2014 Scientific Program

Presentation No.

7:00 - 8:30

Hermes

inaugural trainees symposium: Session 2

7:00

Chair: C. Moret Chalmin (France)

21

Chair: A. Sauerbier (United Kingdom)

22

COGNITIVE BEHAVIORAL GROUP THERAPY FOR STRESS REDUCTION IN PATIENTS WITH PD BASELINE DATA AND FEASIBILITY

23

A. Hadinia, A. Meyer, R. Zimmermann, U. Gschwandtner, R.D. Stieglitz, P. Fuhr (Switzerland) 7:15

ALPHA REACTIVITY IN MILD COGNITIVE IMPAIRMENT AND PD

24

R. Sturzenegger, H. Hurter, G. Gschwandtner, M. Chaturvedi, F. Hatz, H. Bousleiman, R. Zimmermann, F. Fuhr (Switzerland) 7:30

MILD COGNITIVE IMPAIRMENT AND CHANGES IN BRAIN NETWORK CONFIGURATION IN PATIENTS WITH PD

25

F. Hatz, R. Zimmermann, H. Bousleiman, U. Gschwandtner, P. Fuhr (Switzerland) 7:45

FACTOR STRUCTURE AND CONSTRUCT VALIDITY OF THE PDSS-2: IS THE PDSS-2 SENSITIVE TO PROBLEMS THAT IMPACT ON DAYTIME FUNCTION?

26

M. Pushpanathan, A.M. Loftus, M.G. Thomas, N. Gasson, R.S. Bucks (Australia) 8:00

VISUAL DISTURBANCES: AN IMPORTANT NON-MOTOR ASPECT IN PD

27

A. Sauerbier, E. Saunders, K. Ray Chaudhuri (United Kingdom) 8:15

SHORT TERM EFFECTS OF NON-MOTOR SYMPTOMS IN PD FOLLOWING ACUTE DOPAMINERGIC CHALLENGE

28

L. Perkins, R. Inniss, A. Martin, K. Ray-Chaudhuri (United Kingdom)

7:30 - 8:50

Risso 6

Free Communication: Non motor symptoms

7:30

Chair: C. Falup-Pecurariu (Romania)

29

Chair: J. Slawek (Poland)

30

TREATING PD PSYCHOSIS WITH COGNITIVE BEHAVIORAL THERAPY (CBT)

31

H. Montero (Dominican Republic) 7:40

DECREASED EXPRESSION OF 5-HT4 RECEPTORS IN GASTRIC MYENTERIC PLEXUS AND WEAKENED GASTRIC MYOELECTRIC ACTIVITIES IN 6-OHDA RAT

32

L. Zheng, W.E.I. Liu, J. Zhu (China) 7:50

OLFACTORY DYSFUNCTION AND NEUROTRANSMITTER DISTURBANCE IN ANIMAL MODEL OF PD

33

W. Le (China) 8:00

A HYPOTHESIS: FATIGUE IN PD- ARE WE MISSING A TRICK IN FALL-PREVENTION? V.A. Agarwal, H.C. Roberts, E.L. Stack (United Kingdom)

20

34


Presentation No.

8:10

GLOBAL LONG-TERM REGISTRY ON EFFICACY AND SAFETY OF DUODOPA IN PATIENTS WITH ADVANCED PD IN ROUTINE CARE (GLORIA) – INTERIM RESULTS ON NON-MOTOR SYMPTOMS

35

A. Antonini, K. Ray Chaudhuri, A. Yegin, L. Bergmann, W. Poewe (Italy) 8:20

THE DECREASED MUSCARINIC RECEPTOR M1 IN NITRERGIC NEURONS AND INCREASED MUSCULAR M2/M3 IN COLORECTUM CONTRIBUTE TO THE CONSTIPATION IN PD RATS

36

X. Zhang, J. Zhu (China) 8:30

THE RELATIONSHIP OF FATIGUE WITH PERCEIVED AND MEASURED PHYSICAL FUNCTIONING AND ACTIVITY LEVELS IN PEOPLE WITH PD

37

M. Franssen, J. Collett, H. Dawes (United Kingdom) 8:40

ORAL HEALTH IN PD PATIENTS

38

M.A.E. Van Stiphout, C. De Baat, W.M. Van der Boon (Netherlands)

7:30 - 8:30

Risso 7

Free Communication: Miscellaneous

7:30

Chair: M. Petrovic (Serbia)

39

Chair: L. Vecsei (Hungary)

40

NEUROPROTECTIVE MECHANISM OF 3-HYDROXY-3-METHYL GLUTARYL CO-ENZYME A (HMG-COA) REDUCTASE INHIBITORS AGAINST 6-HYDROXYDOPAMINE (6-OHDA) INDUCED PARKINSON-LIKE SYMPTOMS IN RATS

41

A. Kumar, N. Sharma, J. Mishra (India) 7:40

EVIDENCE OF FUNCTIONAL CONVERGENCE OF BASAL GANGLIA CIRCUITS IN SUBTHALAMIC NUCLEUS FROM INTRA-OPERATIVEMULTICHANNEL-MICROELECTRODE RECORDING

42

E. Fonoff, E. Morya, K. Sameshima, M. Nicolelis, M.J. Teixeira (Brazil) 7:50

INTERNET-BASED CBT FOR DEPRESSION AND ANXIETY IN PD: A FEASIBILITY STUDY

43

M. Kraepelien, P. Svenningsson, N. Lindefors, V. Kaldo (Sweden) 8:00

PREVALENCE OF VITAMIN D INSUFFICIENCY AND RISK OF FALLS IN THAI PD PATIENTS

44

P. Lolekha, K. Kulkantrakorn (Thailand) 8:10

THE NOVEL PET TRACER 11C-DONEPEZIL DEMONSTRATES DECREASED PARASYMPATHETIC INNERVATION IN THE GUT AND PANCREAS OF PATIENTS WITH PD

45

P. Borghammer, T. Gjerløff, S. Jakobsen, A. Nahimi, K. Knudsen, T. Fedorova, E.H. Danielsen, N. Pavese, D.J. Brooks (Denmark) 8:20

A LONGITUDINAL DIFFUSION KURTOSIS IMAGING STUDY IN TNWT-61 TRANSGENIC MOUSE MODEL OF PD: COMPARISON WITH CONVENTIONAL DIFFUSION TENSOR IMAGING

46

A. Khairnar, P. Latta, E. Drazanova, J. Kucerova, A. Arab, B. Hutter-paier, D. Havas, M. Windisch, A. Sulcova, Z. Starcuk jr, I. Rektorova (Czech Republic)

21


Presentation No.

8:35 - 10:00

Athena

Plenary session 2

8:35

Chair: K. Bhattacharyya (India)

47

Chair: M. Vidailhet (France)

48

BEYOND MOTOR SYMPTOMS IN PD

49

K. Chaudhuri (United Kingdom) 9:00

ROLE OF INFLAMMATION IN PD PATHOGENESIS AND PROGRESSION

50

L.T. Grinberg (USA) 9:25

DISEASE COURSE MODIFICATION IN PD

51

A. Korczyn (Israel) 9:50 DISCUSSION

10:00 - 10:30

Exhibition Area

Break: Exhibition and e-Poster viewing

10:00 - 10:30

Exhibition Area

e-Poster Presentations 1: Non Motor Symptoms

10:00

Chair: E. Brousolle (France)

52

Chair: M.A. Borg (France)

53

NEUROPSYCHIATRIC SYMPTOMS OF PD AND CAREGIVER’S BURDEN

54

P. Martinez-Martin, C. Rodriguez-Blazquez, M. Forjaz, J. De Pedro-Cuesta, K. Ray Chaudhuri, D. Weintraub (Spain) 10:05

RELATIONSHIP BETWEEN MOTOR AND NON-MOTOR SYMPTOMS IN PD BASED ON A TELEMEDICINE PROGRAM 55 C. Rewitzer, K. Schindlbeck, C. Doletschek, F. Klostermann, F. Marzinzik (Germany)

10:10

EFFECT OF DOPAMINE AGONIST THERAPY ON BODY-WEIGHT CHANGE IN PD

56

A. Tsuge, S. Kaneko, R. Wate, M. Oki, M. Nagashima, S. Asayama, S. Iida, K. Itani, M. Nakamura, K. Fujita, A. Saito, N. Takenouchi, H. Kusaka (Japan) 10:15

PSYCHOBIOLOGICAL MODEL OF PERSONALITY IN PD: CORRELATION WITH MOTOR ASYMMETRY

57

F.M.C. Fonoff, E. Fonoff, E.R. Barbosa, T. Quaranta, M.J. Teixeira, D.C. Fuentes (Brazil) 10:20

SMALL MOLECULE GHRELIN AGONIST HM01 ALLEVIATES GASTROINTESTINAL DYSFUNCTIONS IN A 6-OHDA RAT MODEL OF PD Y. Tache (USA)

22

58


Presentation No.

10:30-12:00

Athena

INDUSTRY SPONSORD SESSION Supported Session. Not included in the CME/CPD program. For program details please refer to the Recognition, Acknowledgments & Commercial Support section in the Final Program.

12:00 - 13:00

Exhibition Area


13:00-14:30

Athena

INDUSTRY SPONSORD SESSION Supported Session. Not included in the CME/CPD program. For program details please refer to the Recognition, Acknowledgments & Commercial Support section in the Final Program.

14:35 - 16:00

Athena

Parallel Session: Multi-system atrophy (MSA)

14:35

Chair: D. Woitalla (Germany)

59

Chair: P. Boulinguez (France)

60

AUTONOMIC REGULATION AND CENTRAL AND PERIPHERAL CATECHOLAMINE METABOLISM IN MSA

61

D.S. Goldstein (USA) 14:55

BLOOD PRESSURE PATTERNS IN MSA

62

T. Gurevich (Israel) 15:15

NEUROINFLAMMATION IN MSA

63

L.T. Grinberg (USA) 15:35

GENETICS IN MSA

64

S. Tsuji (Japan) 15:55

WHAT HAVE WE LEARNT AND WHAT NEEDS TO BE DONE?

23


Presentation No.

14:35 - 16:00

Hermes

Parallel Session: Non Pharmacological Treatment

14:35

Chair: I. Schlesinger (Israel)

65

Chair: Z. Pirtosek (Slovenia)

66

MINDFULNESS TRAINING AND ITS EFFECTS ON THE BRAIN OF PD PATIENTS

67

B. Pickut, S. Vanneste, P. Marien, W. Van Hecke, E. Kerckhofs, P.M. Parizel, P.M. Cras (Belgium) 14:55

THE ROLE OF ACUPUNCTURE IN PD

68

S. Park (Korea) 15:15

THE USE OF HERBAL MEDICINE IN PD

69

K. Chua, K. Chan, K.A.H.O. Chan, Y. Lau, K. Tse, L. Chen, V. Mok, M.I.N. Li (Hong Kong China) 15:35

RELAXATION GUIDED IMAGERY ALLEVIATES SYMPTOMS IN PD

70

I. Schlesinger, O. Benyakov (Israel) 15:55


14:35 - 16:00

Risso 6

Parallel Session: Genetics of non motor symptoms in PD

14:35

Chair: R. Alcalay (USA)

71

Chair: A. Brice (France)

72

GENETIC FACTORS INVOLVED IN COGNITIVE FUNCTION IN PD

73

C.H. Williams-Gray (United Kingdom) 14:55

NON MOTOR SYMPTOMS IN GENETIC FORMS OF PD

74

R. Alcalay (USA) 15:15

GENETIC BASIS OF IMPULSE CONTROL DISORDERS IN PD

75

J.C. Corvol (France) 15:35

GENETICS OF DEMENTIA WITH LEWY BODIES G. Lopez (USA)

15:55

24


76


Presentation No.

14:35 - 16:00

Risso 7

Free Communication: Cognitive Dysfunction in PD

14:35

Chair: P. Fernagut (France)

77

Chair: A. Takeda (Japan)

78

DOPAMINE AGONISTS AND RECOLLECTION IMPAIRMENTS IN PD

79

T. Shepherd, N.M.J. Edelstyn, K. Watts, S.J. Ellis (United Kingdom) 14:45

PATTERN OF EXECUTIVE IMPAIRMENT IN MILD TO MODERATE PD

80

A. Kudlicka, L. Clare, J.V. Hindle (United Kingdom) 14:55

COGNITIVE IMPAIRMENT IN IDIOPATHIC PD IN A TERTIARY CARE CENTRE IN KOLKATA

81

K.B. Bhattacharyya, D. Das, S. Rai, A. Biswas, A. Roy, A.K. Senapati (India) 15:05

EVIDENCE OF AN AMNESIA-LIKE RECALL/RECOLLECTION IMPAIRMENT IN NONDEMENTING IDIOPATHIC PD

82

N. Edelstyn, T.A. Shepherd, S.J. Ellis, A.R. Mayes (United Kingdom) 15:15

VERBAL FLUENCY TESTS IN PD: WHAT IS MEASURED AT DIFFERENT STAGES OF THE DISEASE?

83

J. Koerts, L. Tucha, D.F. Bangma, K.S.F. Colman, K.W. Lange, O. Tucha (Netherlands) 15:25

MOTOR SEQUENCING PROBLEM IN PROGRESSIVE SUPRANUCLEAR PALSY - IS IT RELATED TO MOTOR SLOWING, PROCEDURAL LEARNING IMPAIRMENT OR EXECUTIVE DYSFUNCTION?

84

E. Sitek, M. Dabrowska, A. Konkel, D. Wieczorek, E. Narozanska, W. Soltan, P. Robowski, M. Schinwelski, J. Dulski, K. Kluj-Kozlowska, J. Slawek (Poland) 15:35

ASSESSING THE PREDICTIVE VALIDITY OF LEVEL II MDS PD-MCI CRITERIA

85

J. Hoogland, J.A. Boel, J.G. Goldman, B.A. Schmand, A.I. Tröster, D.J. Burn, I. Litvan, G.J. Geurtsen (Netherlands) 15:45

ALPHA REACTIVITY IN PATIENTS WITH PD AND MILD COGNITIVE IMPAIRMENT

86

R. Sturzenegger, M. Hurter, U. Gschwandtner, M. Chaturvedi, F. Hatz, H. Bousleiman, R. Zimmermann, P. Fuhr (Switzerland)

16:00 - 16:30

Exhibition Area


25


Presentation No.

16:00 - 16:30

Exhibition Area

e-Poster Presentations 2: QoL – QUALITY OF LIFE

16:00

Chair: S. Thobois (France)

87

Chair: A. Benazzouz (France)

88

THE FAMILY SUPPORT PROGRAM FOR CAREGIVER OF PARKINSONISM PATIENT. : A CASE REPORT

89

D.A. Kim, J.H. Kim, O.T. Park, J.E. Oh, K.H. Park, H.K. Kim (Korea) 16:05

SELF-REPORTED FREEZING OF GAIT PREDITS QUALITY OF LIFE OVER THE CONTRIBUTIONS OF MOTOR SEVERITY, SLEEP QUALITY AND DEPRESSION IN EARLY PD

90

C.C. Walton, J.M. Shine, J.M. Hall, C. O'Callaghan, L. Mowszowski, M. Gilat, J.Y.Y. Szeto, S.L. Naismith, S.J.G. Lewis (Australia) 16:10

MEASURING HEALTH RELATED QUALITY OF LIFE USING PDQ39 IN PD AS A QUALITY IMPROVEMENT MEASURE IN A NEW DISTRICT GENERAL HOSPITAL SERVICE

91

C. Miller, R. Mappilakkandy (United Kingdom) 16:15

SUBTHALAMIC DEEP BRAIN STIMULATION CHANGES THE RELATIONSHIP BETWEEN SUB-SCORES OF THE PDQ-39 QUALITY OF LIFE QUESTIONNAIRE IN ADVANCED PD

92

J. Daneault, C. Duval, A.F. Sadikot (Canada) 16:20

PERCEPTION GAP FOR THE MOTOR AND NON-MOTOR SYMPTOM BETWEEN PATIENTS WITH PARKINSON’S DISEASE AND CAREGIVERS

93

M. Hirayama, T. Minato, T. Maeda, K. Kashihara (Japan)

16:30 - 18:00

Athena

Parallel Session: Frontotemporal dementia Parkinsonism

16:30

Chair: E. Gelpi (Spain)

94

Chair: R. Rosales (Philippines)

95

THE DIFFERENT PHENOTYPES OF FRONTO-TEMPORAL LOBAR DEGENERATION

96

B. Dubois, J. Lagarde, R. Levy (France) 16:50

CLINICAL MANIFESTATIONS OF FTLD

97

J. Kulisevsky, J. Pagonabarraga (Spain) 17:10 NEUROPATHOLOGY

98

M. Neumann (Germany) 17:30 GENETICS I. Le Ber (France) 17:50 26


99


Presentation No.

16:30 - 18:00

Hermes

Parallel Session: Sleep problems and the sleep structure in PD

16:30

Chair: J. Larsen (Norway)

100

Chair: P. Damier (France)

101

WHAT ALTERS THE MACROSTRUCTURE OF SLEEP IN PD

102

F. Sixel-Döring, E. Trautmann, B. Mollenhauer, C. Trenkwalder (Germany) 16:50

POLYSOMNOGRAPHY IN EARLY VERSUS LATE PD

103

P. Jennum (Denmark) 17:10

SLEEP DISORDERS IN THE PREMOTOR-PHASE OF PD

104

A. Iranzo (Spain) 17:30

DEVELOPMENT OF HYPERSOMNIA IN PATIENTS WITH EARLY PD

105

M.D. Gjerstad (Norway) 17:50


16:30 - 18:00

Risso 6

Parallel Session: Olfaction

16:30

Chair: J.E. Duda (USA)

106

Chair: M. Muller (USA)

107

OLFACTORY TRAINING AND COGNITION IN PD

108

A. Haehner (Germany) 16:50

NEUROPATHOLOGY OF OLFACTION IN PD

109

N. Hattori (Japan) 17:10

OLFACTORY DYSFUNCTION IN LRRK2 PARKINSONISM

110

J. Duda (USA) 17:30

IMAGING OF OLFACTORY DYSFUNCTION IN PD

111

M. Muller, N. Bohnen (USA) 17:50


27


Presentation No.

16:30 - 18:00

Risso 7

Parallel Session: Deep Brain Stimulation

16:30

Chair: M. Samuel (United Kingdom)

112

Chair: P. Krack (France)

113

NON-MOTOR AND MOTOR OUTCOMES IN DBS

114

L. Timmermann (Germany) 16:50

PSYCHOLOGICAL AND PSYCHIATRIC ASPECTS OF ICD IN THE CLINIC

115

R.M.A. De Bie (Netherlands) 17:10

PATIENT PERCEPTIONS AND EXPECTATION IN DBS

116

M. Okun (United Kingdom) 17:30

TECHNOLOGY ADVANCES IN DBS K. Ashkan (United Kingdom)

17:50

28


117


www.kenes.com/nmdpd

scientific progra


Scientific Program saturday, December 6, 2014

Presentation No.

Scientific Program Saturday, December 6, 2014 7:30 - 8:30

Athena

Plenary session 3

7:30

Chair: N. Hattori (Japan)

118

Chair: A. Antonini (Italy)

119

PRODROMAL DEMENTIA WITH LEWY BODIES

120

I. McKeith (United Kingdom) 7:50

CAN WE PREDICT PD DEMENTIA?

121

D.J. Burn (United Kingdom) 8:10

MILD COGNITIVE IMPAIRMENT IN PD-WHAT'S NEW?

122

D. Weintraub (USA)

8:30 - 10:00

Athena

Plenary Session 4

8:30

Chair: T. Treves (Israel)

123

Chair: R. Levy (France)

124

APATHY AND PUNDING: TWO OPPOSITE SIDES OF THE SAME COIN

125

P. Krack (France) 8:55

NEUROPSYCHIATRIC DEFICITS IN PD

126

D. Aarsland (Sweden) 9:20

WHY DO PD PATIENTS TAKE SOMETIMES THE WRONG DECISION?

127

P. Damier (France) 9:45 DISCUSSION

31

saturday, December 6, 2014 Scientific Program

Presentation No.

10:00 - 10:30

Exhibition Area


10:00 - 10:30

Exhibition Area

e-Poster Presentations 3: Deep Brain Stimulation; Depression

10:00

Chair: A. Negrotti (Italy)

128

Chair: F. Durif (France)

129

CESSATION OF HEAVY SMOKING AFTER STN DBS

130

N. Zupancic Kriznar, M. Trost, M. Gregoric Kramberger, R. Rajnar, L. Ocepek, Z. Pirtosek (Slovenia) 10:05

PSYCHIATRIC COMORBIDITY IN PRIMARY DYSTONIA PATIENTS PRIOR AND FOLLOWING DEEP BRAIN STIMULATION OF THE GLOBUS PALLIDUS INTERNUS

131

A. Gamaleya, A. Bondarenko, A. Tomskiy, S. Buklina, V. Shabalov (Russia) 10:10

N-ACETYLCYSTEINE-MEDIATED ANTIDEPRESSANT-LIKE EFFECTS IN A RAT DEPRESSION MODEL: POSSIBLE MECHANISMS?

132

N. Alrasheed, M. Al-Samhari, S. Al-Rejaie, R. Ahmed, N. Dzimiri (Saudi Arabia) 10:15

DEPRESSION AND MILD COGNITIVE IMPAIRMENT IN PARKINSONIAN SYNDROMES

133

A.S. Harutyunyan, A.Y. Avetisyan, A.H. Karapetyan, E.M. Gevorgyan, H.M. Manvelyan (Armenia)

10:30-12:00

Athena

INDUSTRY SPONSORED SESSION Supported Session. Not included in the CME/CPD program. For program details please refer to the Recognition, Acknowledgments & Commercial Support section in the Final Program.

12:00 - 13:00 Break: Exhibition and e-Poster viewing

32

Exhibition Area


Presentation No.

13:00 - 14:30

Athena

Parallel Session: Basal ganglia and emotion

13:00

Chair: D. Burn (United Kingdom)

134

Chair: B. Dubois (France)

135

FACIAL EXPRESSION RECOGNITION AND DISORDERS OF THE BASAL GANGLIA

136

J.V. Hindle, L. Subramanian, S. Jones (United Kingdom) 13:20

AUTO ACTIVATION DEFICIT AND THE BASAL GANGLIA

137

V. Czernecki (France) 13:40

SUBTHALAMIC NUCLEUS AND EMOTION PROCESSING

138

M. Vérin (France) 14:00

ANXIETY IN PD

139

E. Stefanova (Serbia) 14:20


13:00 - 14:30

Hermes

Parallel Session: Animal models of PD

13:00

Chair: M.F. Chesselet (USA)

140

Chair: A. Destee (France)

141

SLEEP AND COGNITIVE DYSFUNCTION INDUCED BY ALPHA-SYNUCLEIN OVEREXPRESSION IN MICE

142

M.F. Chesselet, I. Magen, K. McDowell (USA) 13:20

ALTERATIONS IN CHOLINERGIC AND PEPTIDERGIC NEURONS ACCOMPANY GLIOSIS AND INCREASED ALPHA-SYNUCLEIN IN THE MYENTERIC PLEXUS OF MPTP-TREATED COMMON MARMOSETS.

143

E. Coletto, A. Hikima, M.J. Jackson, K.R. Chaudhuri, P. Jenner, S. Rose (United Kingdom) 13:30

ROLE OF THE CHOLINERGIC SYSTEM IN SLEEP DEFICITS INNON-HUMAN PRIMATE MODELS OF PD

144

H. Belaid, J. Adrien, E. Laffrat, D. Tandé, C. Karachi, D. Grabli, I. Arnulf, S. Clark, E.C. Hirsch, C. Francois (France) 13:50

METABOLIC ABNORMALITIES IN A TRANSGENIC MOUSE MODEL OF PD

145

K. Belarbi, M. Mequinion, A. Stievenard, K. Saitoski, D. Beekharee, E. Caron, D. Taillieu, O. Viltart, B. Gressier, C. Vanbesien-Mailliot, M.C. Chartier-Harlin, A. Destée (France) 14:00

GASTROINTESTINAL DYSFUNCTIONS IN PD: CONTRIBUTION OF THE ROTENONE MODEL

146

C. Vanbesien, A. Bencsik, A. Stievenard, Y. Denning, E. Antier, M. Schwarz, M. Leboidre, M.C. Chartier-Harlin, F. Pan-Montojo (France) 14:10

WHAT HAVE WE LEARNT AND WHAT NEEDS TO BE DONE? 33


Presentation No.

13:00 - 14:30

Risso 6

Parallel Session: Non motor aspects of dystonia

13:00

Chair: K. Bayulkem (Turkey)

147

Chair: K. Bhatia (United Kingdom)

148

THE NON-MOTOR SYNDROME OF DYSTONIA

149

M. Stamelou (Greece) 13:20

MENTAL DYSFUNCTION IN DYSTONIA PLUS SYNDROMES

150

R. Rosales (Philippines) 13:40

DEPRESSION IN DYSTONIA

151

D. Truong (USA) 14:00

THE ROLE OF THE CEREBELLUM IN DYSTONIA

152

M. Vidailhet (France) 14:20


13:00 - 14:30

Risso 7

Parallel Session: Deep brain stimulation and non-motor symptoms of PD

13:00

Chair: P. Pollak (Switzerland)

153

Chair: C. Karachi (France)

154

DBS AND NON-MOTOR SYMPTOMS OF PD

155

C. Baunez (France) 13:20

DOPAMINE WITHDRAWAL SYNDROME AFTER STN DBS: CLINICAL SYNDROME, PATHOPHYSIOLOGY AND MANAGEMENT156 S. Thobois, E. Lhommée, H. Klinger, P. Mertens, S. Chabardes, E. Broussolle, P. Pollak, P. Krack (France)

13:40

HYPERDOPAMINERGIC BEHAVIORAL DISORDERS IN PD: COMPLICATION OR INDICATION FOR DBS

157

P. Krack (France) 14:00

PERSONALISED MEDICINE IN DBS M. Samuel (United Kingdom)

14:20

34


158


Presentation No.

14:35 - 16:00

Athena

Parallel Session: Impulse Control disorders

14:35

Chair: M. Samuel (United Kingdom)

159

Chair: D. Weintraub (USA)

160

PSYCHOLOGICAL AND PSYCHIATRIC ASPECTS OF ICD IN THE CLINIC

161

D. Okai (United Kingdom) 14:55

RISK FACTORS OF ICD IN PD

162

F. Durif (France) 15:15

FROM DYSKINESIAS TOICD: COMMON MOLECULAR MECHANISMS?

163

P.O. Fernagut (France) 15:35

CLINICAL TRIALS FOR ICD

164

D. Weintraub (USA) 15:55


14:35 - 16:00

Hermes

Parallel Session: Sleep

14:35

Chair: E. Tan (Singapore)

165

Chair: D. Aarsland (Norway)

166

IS RLS A NMS OF PD?

167

J.E. Duda (USA) 14:55

GENETICS OF RLS: PROMISES & LIMITATIONS

168

E.K. Tan (Singapore) 15:15

CAN RBD BE A PROGNOSTIC MARKER?

169

B. Jeon, Y.E. Kim (Korea) 15:55


35


Presentation No.

14:35 - 16:00

Risso 6

Parallel Session: Integrating 5HT and DA functions in the basal ganglia FUNDAMENTALS

14:35

Chair: E. Pourcher (Canada)

170

Chair: A. Guekht (Russia)

171

ANATOMICAL ASPECTS

172

M. Parent (Canada) 14:55

EXPERIMENTAL PHARMACOLOGICAL ASPECTS

173

P. Huot (Canada) 15:15

WHEN GOOD LEARNING GOES BAD: ABERRANT SYNAPTIC PLASTICITY AND PD

174

J.A. Beeler (USA) 15:35

ROLE IN BEHAVIOR

175

A. Dagher (Canada) 15:55


14:35 - 16:15

Risso 7

Parallel Session: Biomarkers in PD and related disorders-are we there yet?

14:35

Chair: R. Ravid (Israel)

176

Chair: A. Perret-Liaudet (France)

177

PERIPHERAL AND IMAGING BIOMARKERS OF DEPRESSION IN PD

178

P. Svenningsson (Sweden) 14:55

BIOMARKERS IN PD

179

P. Derkinderen (France) 15:15

BIO BANKS ARE AN ESSENTIAL TOOL IN BIOMARKER DISCOVERY

180

R. Ravid (Netherlands) 15:35

CSF BIOMARKERS TO PREDICT COGNITIVE DECLINE AND PD PHENOTYPES

181

B. Mollenhauer (Germany) 15:55

FROM GENETICS TO POTENTIAL PERIPHERAL BLOOD-BASED BIOMARKERS FOR PD M.-C. Chartier-Harlin, A. Nkiliza, E. Mutez, L. Hopes, S. Bleuse, C. Simonin, T. Comptdaer, A. De Broucker, F. Leprêtre, C.-C. Vanbesien-Mailliot, A. Stievenard, K. Belarbi, P. Semaille, A. Kreisler, C. Demay, M. Figeac, A. Destée (France)

36

182


Presentation No.

16:00 - 16:30

Exhibition Area


16:00 - 16:30

Exhibition Area

e-Poster Presentations 4: Cognitive Dysfunction 1

16:00

Chair: E. Stefanova (Serbia)

183

Chair: M. Verin (France)

184

COGNITIVE SCREENING IN PARKINSON’S DISEASE: COMPARISON OF 3 SCALES

185

A. Gasser, P. Calabrese, E. Kalbe, J. Kessler, P. Rossier (Switzerland) 16:05

COGNITIVE INFLUENCE ON SWALLOWING FUNCTION IN PATIENTS WITH PD

186

J.K. Park, J.S. Kim, J.Y. Youn, J.W. Cho (Korea) 16:10

SEVERITY OF COGNITIVE DEFICIT AMONG PATIENTS WITH PD

187

H.D. Hambardzumyan, H.M. Manvelyan (Armenia) 16:15

SUBCORTICAL WHITER MATTER HYPERINTENSITIES WITHIN THE CHOLINERGIC PATHWAYS IN PDDEMENTIA, DLB AND AD PATIENTS

188

H. Park, I. Park, Y. Oh, D. Yang, K. Lee, H. Choi, J. Kim (Korea) 16:20

MILD COGNITIVE IMPAIRMENT AND NEUROPSYCHIATRIC SYMPTOMS IN EARLY, UNTREATED PD: RESULTS FROM THE PPMI STUDY

189

D. Weintraub (USA)

37


Presentation No.

16:30 - 18:15

Athena

Plenary Session 5

16:30

Chair: G. Dibó (Hungary)

190

Chair: S. Hassin-Baer (Israel)

191

COGNITIVE DISTURBANCES IN PD

192

J.G. Goldman (USA) 16:55

IMPULSIVITY IN DECISION MAKING

193

V. Voon (United Kingdom) 17:20

PHARMACOECONOMICS OF NMS

194

A. Guekht (Russia) 17:45

FUTURE OF NEUROIMAGING IN PD-DEMENTIA D.J. Brooks (Denmark)

18:10 DISCUSSION

38

195


www.kenes.com/nmdpd

scientific progra


Scientific Program sunday, December 7, 2014

Presentation No.

Scientific Program Sunday, December 7, 2014 7:30 - 9:00

Athena

Parallel Session: Neuropathology

7:30

Chair: L. Grinberg (USA)

196

Chair: J. Koerts (Netherlands)

197

C9 PATHOLOGY BECAUSE IT MANIFEST WITH PSYCHIATRIC AND SOMETIMES OTHER SIMILAR TO PD NON MOTOR SYMPTOMS AND EVOLVE TO PARKINSONISM

198

S. Shinagawa, G. Naasan, A. Karydas, G. Coppola, M. Priba, W.W. Seeley, J.Q. Trojanowski, B.L. Miller, L.T. Grinberg (USA) 7:50

MULTIPLE ORGAN INVOLVEMENT BY ALPHA-SYNUCLEIN PATHOLOGY IN LEWY BODY DISORDERS

199

E. Gelpi, J. Navarro-Otano, E. Tolosa, C. Gaig, Y. Compta, M.J. Marti, F. Valldeoriola, T. Ribalta, M.J. Rey, I. Hernandez (Spain) 8:10

NEUROPATHOLOGY AND NEUROIMAGING OF REM BEHAVIOR DISORDER

200

M.E. Murray (USA) 8:30

ROLE OF NEUROTRANSMITTERS IN NON-MOTOR SYMPTOMS OF PD

201

A. Benazzouz, E. Faggiani, C. Delaville (France) 8:50


7:30 - 9:00

Hermes

Parallel Session: Gastrointestinal aspects in PD

7:30

Chair: A. Friedman (Poland)

202

Chair: P. Odin (Germany)

203

DYSPHAGIA IN PD: DIAGNOSIS AND MANAGEMENT

204

N. Miller (United Kingdom) 7:50

SMALL INTESTINE DYSFUNCTION IN PD

205

A. Friedman, J. Dutkiewicz (Poland) 8:10

CONTRIBUTION OF DIET TO MOTOR FLUCTUATIONS IN PD AND STRATEGIES FOR MANAGEMENT

206

D. Woitalla, S. Zella (Germany) 8:30

CONSTIPATION IN PD: OCCURENCE AND MANAGEMENT

207

P. Odin (Germany) 8:50

WHAT HAVE WE LEARNT AND WHAT NEEDS TO BE DONE? 41

sunday, December 7, 2014 Scientific Program

Presentation No.

7:30 - 9:00

Risso 6

Parallel Session: Contribution of nuclear medicine to PD, PDD and DLB

7:30

Chair: Z. Walker (United Kingdom)

208

Chair: S. Lehericy (France)

209

DOPAMINERGIC IMAGING IN DLB

210

Z. Walker (United Kingdom) 7:50

DOPAMINERGIC IMAGING IN PD/PDD

211

J. Booij, O.A. Van den Heuvel, H.W. Berendse (Netherlands) 8:10

AMYLOID AND TAU IMAGING

212

V.L. Villemagne (Australia) 8:30

FDG IMAGING

213

F. Nobili, D. Arnaldi, A. Picco, S. Morbelli (Italy) 8:50


7:30 - 9:00

Risso 7

Parallel Session: The spectrum of sexual disorders in PD: from hypo- to hyper-sexuality

7:30

Chair: G. Bronner (Israel)

214

Chair: F. Stocchi (Italy)

215

THE SPECTRUM OF SEXUAL DYSFUNCTION IN PD

216

S. Hassin-Baer (Israel) 7:50

MEDICAL TREATMENT OF SEXUAL DYSFUNCTION AND HYPERSEXUAL BEHAVIOR IN PD

217

F. Stocchi (Italy) 8:10

PRACTICAL APPROACH TO SEXUAL DYSFUNCTION AND HYPERSEXUALITY IN PD

218

G. Bronner (Israel) 8:30

HOW IMPORTANT IS SEXUAL DYSFUNCTION TO THE QOL OF PD PATIENTS P. Martinez Martin (Spain)

8:50

42


219


Presentation No.

9:05 - 10:30

Athena

Parallel Session: Pain in PD

9:05

Chair: O. Rascol (France)

220

Chair: A. Chadahidi (Morocco)

221

EPIDEMIOLOGICAL STUDIES

222

G. Defazio (Italy) 9:20 PATHOPHYSIOLOGY

223

M. Tinazzi (Italy) 9:35 MANAGEMENT

224

O. Rascol (France) 9:50

PAIN IN PD

225

S. Perez Lloret (Argentina) 10:05

SENSORY DEFICIT IN PD: ANOTHER ASPECT ON NON MOTOR FUNCTIONS

226

J. Azulay (France) 10:20


9:05 - 10:30

Hermes

Parallel Session: Neuroimaging of non-motor deficits in PD

9:05

Chair: O. Monchi (Canada)

227

Chair: J. Azulay (France)

228

DEPRESSION IN PD: SEARCH FOR MORPHOLOGY

229

V. Kostic (Serbia) 9:25

MOLECULAR IMAGING AND NEURAL NETWORKS OF IMPULSE CONTROL IN PD

230

A. Strafella (Canada) 9:45

FUNCTIONAL CONNECTIVITY STUDIES OF COGNITION - BEYOND THE DEFAULT MODE NETWORK

231

I. Rektorova (Czech Republic) 10:05

ANATOMICAL AND FUNCTIONAL MRI STUDIES OF MILD COGNITIVE IMPAIRMENTS IN PD

232

O. Monchi (Canada) 10:25


43


Presentation No.

9:05 - 10:30

Risso 6

Parallel Session: Vascular Factors in pd

9:05

Chair: I. Rektor (Czech Republic)

233

Chair: M. Relja (Croatia)

234

CLINICS OF VASCULAR PARKINSNISM

235

P. Barone (Italy) 9:25

CLINICAL IMAGING CORRELATES

236

A. Antonini (Italy) 9:45

IMPACT OF VASCULAR FACTORS ON COURSE AND MORTALITY IN PD

237

I. Rektor (Czech Republic) 10:05

VASCULAR MECHANISMS OF HYPERINTENSITIES IN MRI IN PD DEMENTIA

238

J. Slawek (Poland) 10:20


9:05 - 10:30

Risso 7

Parallel Session: Detection of neuropsychological deficits in PD – scales and biomarkers

9:05

Chair: P. Calabrese (Switzerland)

239

Chair: u. gschwandtner (Switzerland)

240

VALIDITY OF SCREENING INSTRUMENTS FOR DETECTION OF NEUROPSYCHIATRIC SYNDROMES

241

P. Martinez Martin (Spain) 9:25

SPECIFICITY OF COGNITIVE DEFICITS IN PD-MCI

242

P. Calabrese (Switzerland) 9:45

QUANTITATIVE EEG PARAMETERS AS A BIOMARKER FOR MCI IN PD

243

P. Fuhr (Switzerland) 10:05

CORTICAL SOURCES OF RESTING STATE EEG RHYTHMS IN PDD AND AD: DO THEY REFLECT SPECIFIC NETWORK DISEASE PROCESSES?

244

C. Babiloni, C. Del Percio, R. Lizio, N. Marzano, S. Cordone, S. Lopez, G. Noce, G.B. Frisoni, U. Gschwandtner, P. Fuhr (Italy) 10:25

IMPACT OF COGNITIVE TRAINING IN PD J. Edwards (USA)

44

245


Presentation No.

10:00 - 10:30

Exhibition Area


10:30 - 11:00

Exhibition Area

e-Poster Presentations 5: Cognitive Dysfunction 2

10:30

Chair: D. Truong (USA)

246

Chair: T. Gurevich (Israel)

248

DEEP BRAIN STIMULATION AND ON-LINE EXECUTIVE CONTROL IN PD

249

T. Hasbroucq, F. Fluchère, I. Suarez del Chiaro (France) 10:35

CORTICAL SOURCES OF P300 EVENT-RELATED POTENTIAL IN PATIENTS WITH PD

250

S.A. Kryzhanovskyi, O.V. Ivanenko, A.O. Cherninskyi, I.G. Zyma, N.V. Karasevich (Ukraine) 10:40

INCREASED DIFFUSIVITY IN THE LATERAL CHOLINERGIC PATHWAY IS ASSOCIATED WITH DEMENTIA IN PD

251

A. Umemura, T. Oeda, R. Hayashi, S. Tomita, M. Kohsaka, K. Park, K. Yamamoto, H. Sugiyama, H. Sawada (Japan) 10:45

GENDER DIFFERENCES IN COGNITION AND DEPRESSION IN PATIENTS WITH PD

252

J. Koerts, D. Bangma, S. Fengler, L. Tucha, O. Tucha (Netherlands) 10:50

PROTOTYPE ABSTRACTION MEMORY FOR ABSTRACT GEOMETRIC PATTERNS REMAINS INTACT IN ESSENTIAL TREMOR PATIENTS

253

P. Ament, D. Lundervold, M. Compton, P. Holt, L. Neumann (USA)

11:00 - 12:30

Hermes

Plenary Session 6

11:00

Chair: J. Touchon (France)

254

Chair: K. Ray Chaudhuri (United Kingdom)

255

EXCITOTOXIC MECHANISMS IN NMDPD: THE ROLE OF KYNURENINES

256

L. Vecsei (Hungary) 11:25

IMPULSIVITY AND LACK OF INHIBITORY CONTROL PROCESSES IN PD

257

P. Boulinguez (France) 11:50

MECHANISMS OF CATECHOLAMINE DEPLETION IN SYNUCLEINOPATHIES

258

D.S. Goldstein (USA) 12:15 DISCUSSION

45


Presentation No.

12:30 - 13:00 congress Closing Ceremony

46

Hermes

www.kenes.com/nmdpd

e-Posters Presentation

Presentation No.

Friday, December 05, 2014 e-Poster Presentations 1: NMS - Non Motor Symptoms 10:00 - 10:30

Exhibition area

Chair: Emmanuel Brousolle (France)

52

Chair: Michael A. Borg (Malta)

53

NEUROPSYCHIATRIC SYMPTOMS OF PD AND CAREGIVER’S BURDEN P. Martinez-Martin, C. Rodriguez-Blazquez, M. Forjaz, J. De Pedro-Cuesta, K. Ray Chaudhuri, D. Weintraub (Spain)

54

RELATIONSHIP BETWEEN MOTOR AND NON-MOTOR SYMPTOMS IN PD BASED ON A TELEMEDICINE PROGRAM C. Rewitzer, K. Schindlbeck, C. Doletschek, F. Klostermann, F. Marzinzik (Germany)

55

EFFECT OF DOPAMINE AGONIST THERAPY ON BODY-WEIGHT CHANGE IN PD A. Tsuge, S. Kaneko, R. Wate, M. Oki, M. Nagashima, S. Asayama, S. Iida, K. Itani, M. Nakamura, K. Fujita, A. Saito, N. Takenouchi, H. Kusaka (Japan)

56

PSYCHOBIOLOGICAL MODEL OF PERSONALITY IN PD: CORRELATION WITH MOTOR ASYMMETRY F.M.C. Fonoff, E. Fonoff, E.R. Barbosa, T. Quaranta, M.J. Teixeira, D.C. Fuentes (Brazil)

57

SMALL MOLECULE GHRELIN AGONIST HM01 ALLEVIATES GASTROINTESTINAL DYSFUNCTIONS IN A 6-OHDA RAT MODEL OF PD Y. Tache (USA)

58

e-Poster Presentations 2: QoL - Quality of life in PD 16:00 - 16:30

48

Exhibition area

Chair: Stephane Thobois (France)

87

Chair: Abdelhamid Benazzouz (France)

88

16:00 THE FAMILY SUPPORT PROGRAM FOR CAREGIVER OF PARKINSONISM PATIENT. : A CASE REPORT D.A. Kim, J.H. Kim, O.T. Park, J.E. Oh, K.H. Park, H.K. Kim (Korea)

89

16:05 SELF-REPORTED FREEZING OF GAIT PREDITS QUALITY OF LIFE OVER THE CONTRIBUTIONS OF MOTOR SEVERITY, SLEEP QUALITY AND DEPRESSION IN EARLY PD C.C. Walton, J.M. Shine, J.M. Hall, C. O’Callaghan, L. Mowszowski, M. Gilat, J.Y.Y. Szeto, S.L. Naismith, S.J.G. Lewis (Australia)

90

16:10 MEASURING HEALTH RELATED QUALITY OF LIFE USING PDQ39 IN PD AS A QUALITY IMPROVEMENT MEASURE IN A NEW DISTRICT GENERAL HOSPITAL SERVICE C. Miller, R. Mappilakkandy (United Kingdom)

91

16:15 SUBTHALAMIC DEEP BRAIN STIMULATION CHANGES THE RELATIONSHIP BETWEEN SUBSCORES OF THE PDQ-39 QUALITY OF LIFE QUESTIONNAIRE IN ADVANCED PD J. Daneault, C. Duval, A.F. Sadikot (Canada)

92

16:20 PERCEPTION GAP FOR THE MOTOR AND NON-MOTOR SYMPTOM BETWEEN PATIENTS WITH PARKINSON’S DISEASE AND CAREGIVERS M. Hirayama, T. Minato, T. Maeda, K. Kashihara (Japan)

93

Presentation No.

Saturday, December 06, 2014 e-Poster Presentations 3: Deep Brain Stimulation; Depression 10:00 - 10:30

Exhibition area

Chair: Anna Negrotti (Italy)

128

Chair: Franck Durif (France)

129

10:00

10:05

10:10

10:15

CESSATION OF HEAVY SMOKING AFTER STN DBS N. Zupancic Kriznar, M. Trost, M. Gregoric Kramberger, R. Rajnar, L. Ocepek, Z. Pirtosek (Slovenia)

130

PSYCHIATRIC COMORBIDITY IN PRIMARY DYSTONIA PATIENTS PRIOR AND FOLLOWING DEEP BRAIN STIMULATION OF THE GLOBUS PALLIDUS INTERNUS A. Gamaleya, A. Bondarenko, A. Tomskiy, S. Buklina, V. Shabalov (Russia)

131

N-ACETYLCYSTEINE-MEDIATED ANTIDEPRESSANT-LIKE EFFECTS IN A RAT DEPRESSION MODEL: POSSIBLE MECHANISMS? N. Alrasheed, M. Al-Samhari, S. Al-Rejaie, R. Ahmed, N. Dzimiri (Saudi Arabia)

132

DEPRESSION AND MILD COGNITIVE IMPAIRMENT IN PARKINSONIAN SYNDROMES A.S. Harutyunyan, A.Y. Avetisyan, A.H. Karapetyan, E.M. Gevorgyan, H.M. Manvelyan (Armenia)

133

e-Poster Presentations 4: Cognitive Dysfunction 1 16:00 - 16:30

Exhibition area

Chair: Elka Stefanova (Serbia)

183

Chair: TBA 16:00 COGNITIVE SCREENING IN PARKINSON’S DISEASE: COMPARISON OF 3 SCALES A. Gasser, P. Calabrese, E. Kalbe, J. Kessler, P. Rossier (Switzerland)

185

16:05 COGNITIVE INFLUENCE ON SWALLOWING FUNCTION IN PATIENTS WITH PD J.K. Park, J.S. Kim, J.Y. Youn, J.W. Cho (Korea)

186

16:10 SEVERITY OF COGNITIVE DEFICIT AMONG PATIENTS WITH PD H.D. Hambardzumyan, H.M. Manvelyan (Armenia)

187

16:15 SUBCORTICAL WHITER MATTER HYPERINTENSITIES WITHIN THE CHOLINERGIC PATHWAYS IN PD-DEMENTIA, DLB AND AD PATIENTS H. Park, I. Park, Y. Oh, D. Yang, K. Lee, H. Choi, J. Kim (Korea)

188

16:20 MILD COGNITIVE IMPAIRMENT AND NEUROPSYCHIATRIC SYMPTOMS IN EARLY, UNTREATED PD: RESULTS FROM THE PPMI STUDY D. Weintraub (USA)

189

49

Presentation No.

Sunday, December 07, 2014 e-Poster Presentations 5: Cognitive Dysfunction 2 10:00 - 10:30

Exhibition area

Chair: TBA Chair: Tanya Gurevich (Israel)

50

248

10:30

DEEP BRAIN STIMULATION AND ON-LINE EXECUTIVE CONTROL IN PD T. Hasbroucq, F. Fluchère, I. Suarez del Chiaro (France)

249

10:35

CORTICAL SOURCES OF P300 EVENT-RELATED POTENTIAL IN PATIENTS WITH PD S.A. Kryzhanovskyi, O.V. Ivanenko, A.O. Cherninskyi, I.G. Zyma, N.V. Karasevich (Ukraine)

250

10:40

INCREASED DIFFUSIVITY IN THE LATERAL CHOLINERGIC PATHWAY IS ASSOCIATED WITH DEMENTIA IN PD A. Umemura, T. Oeda, R. Hayashi, S. Tomita, M. Kohsaka, K. Park, K. Yamamoto, H. Sugiyama, H. Sawada (Japan)

251

10:45

GENDER DIFFERENCES IN COGNITION AND DEPRESSION IN PATIENTS WITH PD J. Koerts, D. Bangma, S. Fengler, L. Tucha, O. Tucha (Netherlands)

252

10:50

PROTOTYPE ABSTRACTION MEMORY FOR ABSTRACT GEOMETRIC PATTERNS REMAINS INTACT IN ESSENTIAL TREMOR PATIENTS P. Ament, D. Lundervold, M. Compton, P. Holt, L. Neumann (USA)

253

e-Poster www.kenes.com/nmdpd

e-posters Scientific Program

Presentation No.

52

Scientific Program e-posters

Presentation No.

e-Poster Viewing: e-Posters

DEVELOPING A HUMAN CELL MODEL OF PD

259

B. Ahmed, O. Husnain, R. Stafford, S. Farnaud, M. Howard, A. Gujar, V. Moradiya, K. Patel, S. Sihotra (United Kingdom)

IN VIVO AND IN VITRO INVESTIGATION OF UPPER GASTROINTESTINAL DYSMOTILITY IN A MODEL OF PD

260

Z. Al Harraq, G. Vegezzi, F. Miduri, G. Gnudi, G. Levandis, S. Cerri, F. Blandini, G. Domenichini, S. Bertoni, V. Ballabeni, E. Barocelli (Italy)

EFFECT OF PIERICIDIN TOXIN ON NEUROSPHERES, IN VITRO STUDY

261

M. Rakha, M. Salama, M. Sobh, M. El-Hawary (Egypt)

MEMORY DEFICITS IN EARLY PD CORRELATE WITH TEMPORAL LOBE ATROPHY

262

T. Álvarez-Avellón, R. Ribacoba Montero, M. Menendez-Gonzalez, F. Cuetos Vega (Spain)

LONG-TERM EXTRAPOLATION OF SAFINAMIDE CLINICAL EFFICACY IN MID- TO LATE-STAGE PD PATIENTS

263

A. Antonini, S. Sherman, E. Dlotko, J. Lister, P. Berto, M. Gorritz, G. Lazzeri, F. Gambini, M. Sardina (Italy)

IS THERE AN IMPACT OF PD AND ITS TREATMENTS ON PREFERENCES VIS-A VIS RISK AND UNCERTAINTY?

264

C. Aubert, A. Reynaud, A. Dubernat, T. Boraud, E. Petit, E. Gabillon (France)

NEUROPROTECTIVE ROLES OF MELATONIN ON METHAMPHETAMINE TOXICITY-INDUCED CYTOSOLIC CALCIUM OVERLOAD, MITOCHONDRIAL DYSFUNCTION AND CELL DEATH IN DOPAMINERGIC CELL LINES

265

A. Parameyong, P. Govitrapong, B. Chetsawang (Thailand)

MITOCHONDRIAL DYSFUNCTION, OXIDATIVE STRESS AND ALPHA-SYNUCLEIN IN PD

266

S. Bandres, R. Durán, F.J. Barrero, J. Pelegrina, M. Ramírez, F. Vives (Spain)

RESTLESS LEGS SYNDROME (RLS) IN PATIENTS WITH PD: A COMPARATIVE STUDY ON PREVALENCE AND CLINICAL CHARACTERISTICS

267

S.M. Fereshtehnejad, M. Shafieisabet, G.A. Shahidi, A. Delbari, J. Lökk (Sweden)

SEARCHING FOR MECHANISMS INVOLVED IN THE ‘DEPRESSIVE-LIKE’ BEHAVIOR IN AN ANIMAL MODEL OF A PRE-CLINICAL STAGE OF PD

268

K. Berghauzen-Maciejewska, J. Wardas, U. Glowacka, K. Kuter, B. Mróz, K. Ossowska (Poland)

DIABETES, GRAY MATTER LOSS AND COGNITION IN THE SETTING OF PD

269

M. Petrou, C. Davatzikos, M. Hsieh, R.L. Albin, V. Kotagal, M.M. Muller, R.A. Koeppe, K.A. Frey, N.I. Bohnen (USA)

HIGHER DEPRESSIVE SYMPTOMS ARE LINKED WITH AN INCREASED RATE OF GRAY MATTER THINNING OVER TIME IN PATIENTS WITH PD

270

M.A. Bruneau, A. Hanganu, C. Bedetti, C. Degroot, B. Mejia-Constain, A.L. Lafontaine, V. Soland, S. Chouinard, O. Monchi (Canada)

DIVERGENT THINKING IN DE NOVO PD PATIENTS: PRELIMINARY DATA AFTER 24 MONTHS FOLLOW-UP

271

M. Canesi, F. Moroni, A. Ranghetti, G. Pezzoli, M.L. Rusconi (Italy) 53


Presentation No.

ORTHOSTATIC DIZZINESS AND ORTHOSTATIC HYPOTENSION IN PD

272

C. Sang-Myung, M. Park, J. Kim (Korea)

PREVALENCE AND RISK FACTORS FOR DROOLING IN PD

273

R. Manso-Calderón (Spain)

STUDY ON THE EFFECTIVENESS OF LEVODOPA/CARBIDOPA INFUSION GEL (LCIG) IN NEUROPSYCHIATRIC AND SLEEP DISTURBANCES IN ADVANCED PD PATIENTS (EDIS STUDY). INTERIM ANALYSIS

274

M.J. Catalán, J.M. Arbelo, E. Cubo, P. Mir, J. Herreros, P. Montero, P. Martinez-Martin (Spain)

LONG-TERM EFFECTS OF SAFINAMIDE TREATMENT ON DYSKINESIA IN MID- TO LATE-STAGE PD PATIENTS. POST-HOC ANALYSIS FROM STUDIES 016-018

275

C. Cattaneo, F. Gambini, E. Bonizzoni, M. Sardina (Italy)

MOVEMENT DISORDERS AFTER STROKE IN THIRD LEVEL HOSPITAL MARRAKECH MOROCCO

276

A. Chahidi, M. Chraa, N. Kissani (Morocco)

‘PERCEIVED INCOMPETENCE’ AND ‘PSYCHOLOGICAL DISCOMFORT’: POWERFUL NON-MOTOR DETERRENTS FROM ACTIVITY AMONG PEOPLE WITH PD

277

E. Stack, H.C. Roberts, V. Agarwal (United Kingdom)

DIFFUSION TENSOR IMAGING IN PD: LONGITUDINAL FINDINGS

278

L.L. Chan, H. Rumpel, K.M. Ng, C.S. Yeoh, E.K. Tan (Singapore)

INTERMITTENT POSITIVE PRESSURE VENTILATION(IPPV) RELIEVED RESPIRATORY SYMPTOMS IN PSP PATIENT; A CASE REPORT

279

J. Choi, J. Lee, H. Park (Korea)

MODERATO, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECT OF RASAGILINE ON MILD COGNITIVE IMPAIRMENT IN PATIENTS WITH PD: AN ONGOING STUDY

280

A. Choudhry, D. Weintraub, R. Hauser (USA)

LOW-PROTEINS DIET INFLUENCES ELECTROGASTROGRAPHIC ACTIVITY IN PD

281

G. Albani, N. El Assawy, M. Mallone, C. Vinci, O. Mian, L. Cattani, A. Mauro (Italy)

EVALUATING COQ2 GENE IN ESSENTIAL TREMOR

282

P. Ratnagopal, E. Ng, Y.H. Chao, P. Kumar, E.K. Tan (Singapore)

SAFETY AND EFFICACY OF COGNITIVE REHABILITATION AND T-DCS IN PD WITH MILD COGNITIVE IMPAIRMENTS 283 R. Biundo, L. Weis, E. Fiorenzato, G. Gentile, M. Campo, V. Marcon, A. Antonini (Italy)

GENOME-WIDE LIKED LOCI OF TYPE 2 DIABETES MELLITUS AND MOCA SCORES IN PD

284

S. Chung, J. Kim, Y. Kim, K. Kim, S. You, M. Kim (Korea)

PROBABLE REM SLEEP BEHAVIOUR DISORDER IS PREVALENT IN EARLY STAGE DEMENTIA WITH LEWY BODIES IN WESTERN NORWAY L.J. Chwiszczuk, M. Breitve, M.J. Hynninen, M. Gjerstad, B. Boeve, D. Aarsland, A. Rongve (Norway)

54

285


Presentation No.

A PREDICTIVE METABOLIC MARKER OF APATHY FOLLOWING SUBTHALAMIC NUCLEUS DEEP BRAIN STIMULATION IN PD

286

A. Gesquière-Dando, E. Guedj, R. Carron, A. Loundou, T. Witjas, F. Fluchère, J. Régis, J.P. Azulay, A. Eusebio (France)

FREQUENCY AND CLINICAL FEATURES OF PD AT THE NEUROLOGY DEPARTMENT OF POINT G TEACHING HOSPITAL 287 T. Coulibaly, B.B. Maiga, K. Dembele, L. Cisse, M. Konate, A.S. Sissoko, T.H. Coulibaly, M. Karambe, C.O. Guinto, M. Traore (Mali)

DIAGNOSTIC VALIDITY AND FACTOR ANALYSIS OF MONTGOMERY-ASBERG DEPRESSION RATING SCALE IN MAJOR DEPRESSION OF PD

288

T. Ketharanathan, R. Hanwella, R. Weerasundera, V.A. De Silva (Australia)

E-DUO STUDY: USE OF LEVODOPA-CARBIDOPA INTESTINAL GEL (LCIG) IN SPANISH ADVANCED PD (APD) PATIENTS. NON-MOTOR SYMPTOMS (NMS) AND CLINICAL GLOBAL IMPRESSION (CGI) SUB-GROUP ANALYSES

289

D. Santos, M.J. Catalan, I. Regidor, J. Parra (Spain)

FUNCTIONAL ANALYSIS OF P.R1205H EIF4G1 MUTATION INVOLVED IN PD

290

A. De Broucker, P. Semaille, T. Comptdaer, M. Figeac, F. Leprêtre, M.L. Caillet-Boudin, A. Destée, M.C. ChartierHarlin (France)

USING GENE NON-INTEGRATED TECHNOLOGY TO GENERATE INDIVIDUAL SPECIFIC IPSC FROM FAMILIAL ALS PATIENTS

291

X. Liu, J. Chen, X. Li, S. Gao, M. Deng (China)

PERCEPTION OF PLEASANT VERSUS UNPLEASANT ODORS IN PD: A CASE FOR OLFACTORY ANHEDONIA?

292

J. Djordjevic, A. Fournel, A. Sadikot, M. Panisset, P. Joussain, M. Bensafi (Canada)

IMPULSE CONTROL DISORDERS IN PD: ASSESSING THE LINK BETWEEN BEHAVIOUR AND INSIGHT

293

I. Zablith, F. Pineau, J. Socha, E. Benchetrit, L. Lacomblez, I. Varescon, J.C. Corvol (France)

INDIVIDUAL NEUROPSYCHOLOGICAL TEST FOR DEMENTIA PREDICTION IN PD

294

Domellöf, F. Forsgren, E. Elgh (Sweden)

INTERIM RESULTS OF A PHASE 3B STUDY ASSESSING THE SAFETY AND EFFICACY OF LEVODOPACARBIDOPA INTESTINAL GEL ON NON-MOTOR SYMPTOMS IN SUBJECTS WITH ADVANCED PARKINSON’S DISEASE 295 J. Dubow, K. Chatamra, S. Eaton, C. Hall, J. Benesh (USA)

QUALITY OF LIFE SUB-SECTIONS OF THE PDQ-30 AND SF-36 ARE INDEPENDENT FROM MOTOR SYMPTOMS IN ADVANCED PD

296

C. Duval, J.F. Daneault, A.F. Sadikot (Canada)

RAPID EYE MOVEMENT SLEEP BEHAVIORAL DISORDER IS ASSOCIATED WITH COGNITIVE DYSFUNCTION IN MULTIPLE SYSTEM ATROPHY

297

S. Koga, M. Murray, N. Aoki, D. Dickson (USA)

55


Presentation No.

FEATURES OF RETINAL NERVE FIBER LAYER AND INNER RETINAL LAYER THINNING IN PD

298

P.S. Dynin, I.V. Litvinenko, E.V. Boyko, R.F. Gimadutdinov, G.E. Isaeva, A.A. Yurin (Russia)

THERAPEUTIC EFFECT AND PROBABLE MECHANISIM OF RAPAMYCIN ON MPTP-INDUCED PARKINSONISM IN MICE299 K.Y. Liu, Y.Y. Sun, Y.M. Sun, W.Q. Chen, N. Shi, L. Jin, Y. Zhang, J.F. Li, X.J. Sun (China)

THE EFFECT OF RIGHT AND LEFT CAROTID INTIMA MEDIA THICKNESS ON SEVERITY OF COGNITIVE DYSFUNCTION IN PD

300

H. Ebrahimi, M. Saadatnia, M. Memari, A. Ebrahimi, A. Hossein zadeh (Iran)

CHRONIC INFLAMMATORY GINGIVAL DISEASE IN PATIENTS WITH PD

301

Y. Balash, C. Peretz, A. Rozenberg, Y. Zlotnik, A. Ezra, N. Giladi, T. Gurevich (Israel)

EVALUATION OF NON MOTOR SYMPTOMS IN PD

302

N. Erdogan, F. Tunali, H. Misirli (Turkey)

APATHY AND OLFACTION IN PD

303

A. Gonçalves, A. Mendes, N. Vila-Chã, J. Damásio, I. Moreira, A. Bastos Lima, S. Cavaco (Portugal)

NON MOTOR FLUCTUATIONS IN PD - ASSESSMENT IN CLINIC

304

A. Todorova, M. Parry, N. Dimitrov, K. Ray Chaudhuri (United Kingdom)

TELEREHABILITATION FOR SPEECH IMPAIRMENT

305

A. Estevo Dias, J. Papaterra Limongi, E. Reis Barbosa, W. Tu Hsing (Brazil)

FREQUENCY AND RISK OF FALLS IN PD IN IBADAN

306

T. Farombi, M. Owolabi, A. Ogunniyi (Nigeria)

THE PERSONALITY TRAITS OF HUNGARIAN PATIENT WITH PD ARE DIFFERENT FROM THE POPULATION'S CHARACTERISTICS: DECREASED NOVELTY SEEKING AND INCREASED HARM AVOIDANCE WAS OBSERVED

307

G. Dibó, J. Lajtos, S. Rózsa, J. Kállai, L. Vécsei (Hungary)

COMPARISON BETWEEN AUTOMATIC AND VISUAL SCORING METHODS OF MUSCLE TONE DURING RAPID EYE MOVEMENT SLEEP IN PD

308

M.L. Fantini, M. Figorilli, P. Beudin, A. Marques, M. Puligheddu, F. Durif, R. Ferri (France)

CEREBROSPINAL FLUID BIOMARKERS AND COGNITIVE IMPAIRMENT IN PATIENTS WITH EARLY PD

309

A. Løvli Stav, D. Aarsland, T. Fladby (Norway)

SALIVARY ACETYLCHOLINESTERASE ACTIVITY IN PD - A POTENTIAL MARKER OF PARASYMPATHETIC DENERVATION310 T. Fedorova, C.S. Knudsen, K. Mouridsen, E. Nexo, P. Borghammer (Denmark)

EFFECT OF GALVANIC VESTIBULAR STIMULATION FOR LATERAL TRUNK FLEXION IN PD: A CASE SERIES Y. Kita, Y. Okada, J. Nakamura, H. Kataoka, T. Kiriyama, S. Ueno, K. Shomoto (Japan)

56

311


Presentation No.

CORRELATIONS AMONG HEAVY METALS IN BLOOD AND URINE AND THEIR RELATIONS TO DEPRESSIVE SYMPTOMS IN PD PATIENTS

312

T. Fukushima, X. Tan, Y. Luo, P. Wang, J. Song, H. Kanda, T. Hayakawa, T. Kumagai, T. Kakamu, M. Tsuji, T. Hidaka, Y. Mori (Japan)

ASSOCIATION BETWEEN IMPULSIVE-COMPULSIVE BEHAVIORS AND REM SLEEP BEHAVIOR DISORDER IN PD: A VIDEO-POLYSOMNOGRAPHIC STUDY

313

M. Fantini, M. Zibetti, M. Figorilli, P. Beudin, T. Vidal, A. Marques, P. Derost, B. Debilly, M. Ulla, N. Vitello, M. Puligheddu, A. Cicolin, L. Lopiano, F. Durif (France)

COGNITIVE DECLINE AND EYE MOVEMENT ABNORMALITIES IN PARSONIAN PATIENTS WITH GLUCOCEREBROSIDASE MUTATIONS

314

F. Moreira, M. Rosário Almeida, A. Morgadinho, C. Januário (Portugal)

THE ROLE OF EXECUTIVE DEFICITS ON FACIAL EMOTIONAL IDENTIFICATION IN PARKINSON´S PATIENTS COMPARING WITH ESSENTIAL TREMOR PATIENTS

315

B. García-Rodriguez, C.T. Casares, R. Jurado, I. Morales, J.A. Molina, G. Rubio, H. Ellgring (Spain)

LONGITUDINAL INVESTIGATION OF VISUAL ACUITY IN THE EARLIEST STAGES OF PARKINSONISM

316

M. Geary, S. Avila, J. Matthews, N. Nowalk, S. Adams (USA)

QUALITY OF LIFE'S EVALUATIONS IN PARKINSON'S DISEASE: SELF AND CAREGIVER AGREEMENT

317

Y. Balash, A. Korczyn, J. Knaani, T. Gurevich (Israel)

A NOVEL BASAL GANGLIA CIRCUIT AND REVERSIBLE NIGROSTRIATAL DOPAMINERGIC DYSFUNCTION AFTER A CEREBRAL INFARCTION IN THE ANTERIOR CINGULATE CORTEX

318

T.B. Ahn, Y.N. Kwon, D.K. Lee (Korea)

GROUP THERAPY TO IMPROVE SPEECH INTELLIGIBILITY AND COMMUNICATION SKILLS FOR PEOPLE WITH PD: USING HUMOR AS A TOOL

319

Y. Manor, J. Posen, L. Elboum, O. Rauf, T. Gurevich (Israel)

REGIONAL METABOLIC CHANGES USING PROTON MAGNETIC RESONANCE SPECTROSCOPY IN KOREAN PATIENTS WITH AMNESTIC MILD COGNITIVE IMPAIRMENT COMPARE WITH HEALTHY CONTROL

320

H. Han, J. Joo, D. Shin (Korea)

GALACTOSE CONSUMPTION CAUSED SEVERE COGNITIVE DYSFUNCTION AND AMYLOID FIBRIL ACCUMULATION IN BRAIN ESPECIALLY IN HYPERCHOLESTEROLEMIC STATE

321

J. Kim, K. Cho (Korea)

NEURO-COGNITIVE REHABILITATION AMONG PATIENTS WITH SPINAL CORD INJURY WHO TREATED WITH STEM CELL

322

A. Zarghi, A. Zali, F. Ashrafi, S.A.M. Moazzezi (Iran)

POTENTIATION OF NEUROTOXICITY IN DOUBLE MUTANT MICE WITH PINK1 ABLATION AND A53T-SNCA OVEREXPRESSION

323

G. Auburger, S. Gispert, N. Brehm, J. Weil, K. Seidel, U. Rüb, B. Kern, M. Walter, J. Roeper (Germany) 57


Presentation No.

NEURO-COGNITIVE REHABILITATION WITH TMS IN DEPRESSED PATIENT

324

A. Zarghi, A. Zali, F. Ashrafi, S.A.M. Moazzezi, N. Bandegani (Iran)

RASAGILINE AND DEPRESSION IN PD

325

V. Drago, P.S. Foster (Italy)

DEFINING THE ROLE OF IMAGING METHODS IN DIAGNOSTICS SYMPTOMATIC EPILEPSY IN CHILDREN.

326

K. Aminov (Uzbekistan)

LANGUAGE USE AND COMMUNICATION PATTERNS IN PATIENTS WITH PD AND THEIR SPOUSES

327

D.L. Hollinde, V. Koller, B. Hauptmann (Germany)

MRI ABNORMALITIES AND EEG PATTERNS OF SYMPTOMATIC EPILEPSY IN CHILDREN WITH BRAIN ANOMALIES. 328 K. Aminov (Uzbekistan)

POSTURE ABNORMALITY OF PD IS CORRELATED WITH TRACP-5B AND BONE ALKAINE PHOSPHATASE, WIDELY USED AS OSTEOPOROSIS MARKERS.

329

K. Hirano, K. Ishikawa, S. Saiki, N. Hattori (Japan)

CHRONIC SUPPLEMENTATION WITH THIAMINE ENHANCES THE ANTICONVULSANT EFFECT OF DIAZEPAM IN PENTYLENTETRAZOLE INDUCED SEIZURE IN MICE

330

A. Mesdaghinia, H.R. Banafshe, M. Alinegad, R. Mokhtari (Iran)

EXECUTIVE COGNITIVE DEFICITS IN PRIMARY DYSTONIA

331

A.M. Gray, F.J.R. Eccles, R.B. Scott (United Kingdom)

EFFECT OF THYMOQUINONE ON MOTOR AND NON-MOTOR SYMPTOMS IN ANIMAL MODEL OF PD

332

K. Hassanzadeh, S. Ebrahimi, S. Oryan, A. Rahimmi, E. Izadpanah (Iran)

VISUAL PROBLEMS AND PD

333

L. Gimoyan, G. Silvanyan (Armenia)

A MULTI-DISCIPLINARY APPROACH FOR MANAGING PD

334

B. Riley (United Kingdom)

COGNITIVE PROFILE IN PD: THE ASSOCIATION BETWEEN MOTOR SUBTYPES AND COGNITIVE PERFORMANCE

335

R. Weintraut, N. Kovács, Z. Aschermann, P. Ács, G. Deli, R. Horváth, T. Lucza, J. Kállai, S. Komoly, K. Karádi (Hungary)

ATTENTIONAL NETWORK DYSFUNCTION IN PATIENTS WITH VISUAL HALLUCINATIONS AND PD

336

J.M. Hall, J.M. Shine, C. O'Callaghan, A.J. Muller, C.C. Walton, J. Phillips, A.A. Moustafa, S.J.G. Lewis (Australia)

COMPARISON OF BECK DEPRESSION INVENTORY AND MONTGOMERY-ASBERG DEPRESSION RATING SCALE IN PATIENTS WITH PARKINSON’S DISEASE T. Lucza, N. Kovács, R. Weintraut, Z. Aschermann, R. Horváth, G. Deli, P. Ács, J. Kállai, S. Komoly, K. Karádi (Hungary)

58

337


Presentation No.

COMPARISON OF SPEECH ABNORMALITIES BETWEEN DRUG-NAÏVE PARKINSON VARIANT MULTIPLE SYSTEM ATROPHY AND PD

338

Y. Huh, J. Park, M. Suh, J. Cho (Korea)

BALANCE ASSESSMENT FOR PARKINSON

339

W. Buated, T. Fujinami, H. Shohei, N. Kashyap (Japan)

LOCAL CHANGES IN URINARY BLADDER CONTRACTILITY FOLLOWING CNS DOPAMINE DENERVATION IN THE 6-OHDA RAT MODEL OF PARKINSON'S DISEASE

340

R. Mitra, P. Aronsson, M. Winder, G. Tobin, F. Bergquist, T. Carlsson (Sweden)

NEUROIMAGING CORRELATES OF DEPRESSION IN PD: A SYSTEMATIC LITERATURE REVIEW

341

M. Diamantoudi, A.J. Farrall, K. Haga (United Kingdom)

CSF BIOMARKERS IN DLB: RESULTS FROM A LARGE MULTICENTRE COHORT

342

I. Van Steenoven, D. Weintraub, E. Lemstra, F. Blanc, E. Londos, B. Mollenhauer, T. Fladby, L. Bonnani, M. Kramberger, D. Aarsland (Sweden)

SLEEP PHENOTYPE IN LRRK2-ASSOCIATED PARKINSONIAN PATIENTS AND HEALTHY LRRK2 MUTATION CARRIERS: IS LRRK2 PARKINSONISM ASSOCIATED WITH REM SLEEP BEHAVIOR DISORDER?

343

M. Ehrminger, S. Leu-Semenescu, F. Cormier, J.C. Corvol, M. Vidailhet, A. Brice, I. Arnulf (France)

RIVASTIGMINE FOR MILD COGNITIVE IMPAIRMENT IN PD: A RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, CROSSOVER STUDY

344

E. Mamikonyan, S. Xie, E. Melvin, D. Weintraub (USA)

COGNITIVE IMPAIRMENT AND THYROID DISEASE IN ELDER ADULTS

345

L. Gimoyan, G. Silvanyan, S. Asatryan (Armenia)

VISUOSPATIAL IMPAIRMENT MAY BE A VALID MEASURE OF DISEASE PROGRESSION IN THE SPECTRUM OF LEWY BODY DISEASE

346

M. Gregoric Kramberger, M. Smrdu, Z. Pirtosek (Slovenia)

EFFECTS OF BOTULINUM TOXIN TO PSYCHIATRIC STATES IN IDIOPATHIC OMD

347

N. Narita (Japan)

LOW SERUM VITAMIN D3 LEVEL COULD BE CONTRIBUTE TO GASTRIC DYSMOTILITY IN DE NOVO PD

348

W. Jang (Korea)

ASSOCIATION OF GI AND AUTONOMIC SYMPTOMS WITH MORNING AKINESIA

349

S. Isaacson (USA)

BIOLOGICAL MOTION PERCEPTION IN PD

350

A. Jaywant, T.D. Ellis, A. Cronin-Golomb (USA)

59


Presentation No.

BODY-WEIGHT CHANGE IN THE EARLY STAGES OF PARKINSON’S DISEASE AND PROGRESSIVE SUPRANUCLEAR PALSY

351

S. Kaneko, A. Tsuge, R. Wate, M. Oki, M. Nagashima, S. Asayama, M. Nakamura, K. Fujita, A. Saito, N. Takenouchi, H. Kusaka (Japan)

BENEFICIAL EFFECTS OF RAMELTEON ON REM SLEEP BEHAVIOR DISORDER ASSOCIATED WITH PD

352

K. Kashihara, Y. Tsuboi, T. Nomura, T. Maeda (Japan)

OPTICAL COHERENCE TOMOGRAPHY AND FUNDUS AUTOFLUORESCENCE IN PD

353

U. Kayabasi, R. Sergott (Turkey)

CAUSE-SPECIFIC MORTALITY OF PARKINSON’S DISEASE IN KOREAN POPULATION: A HOSPITAL BASED STUDY

354

J. Kim, K.J. Kim, H.J. Kim, S.O. Kim, M.S. Kim, H.Y. So, J.P. Hong, S.J. Chung (Korea)

SURVIVAL ANALYSIS OF PD DEMENTIA IN KOREA

355

J.W. Kim, S.M. Cheon, H.J. Ryu (Korea)

MODIFIABLE RISK FACTORS AND COGNITIVE IMPAIRMENT IN PD

356

K.J. Kim, J. Kim, S.J. Chung (Korea)

DAYTIME SLEEPINESS AND DISTURBED NOCTURNAL SLEEP IN PD – THE USE OF PARKINSON`S KINETIGRAPH

357

L. Klingelhoefer, A. Rizos, A. Martin, D. Martino, K. Ray Chaudhuri (Germany)

LRRK2 GENETIC VARIANTS MEDIATE THE PROTECTIVE EFFECT OF CAFFEINE IN PD

358

Y. Koh, S.T.P. Swe, C.A. John, Y. Zhao, P. Kumar, E.K. Tan (Singapore)

EXTENDED P100 LATENCY OF PATTERN REVERSAL VISUAL EVOKED POTENTIAL IS A POSSIBLE PREDICTOR OF VISUAL HALLUCINATION IN PARKINSON'S DISEASE

359

M. Kohsaka, T. Oeda, K. Yamamoto, A. Umemura, S. Tomita, R. Hayashi, K. Park, H. Sugiyama, H. Sawada (Japan)

BRAIN STRUCTURE AND COGNITIVE FUNCTION IN COPD.

360

J. Kolcheva (Russia)

ATTENTION SHIFTING IN PARKINSON’S DISEASE: AN ANALYSIS OF BEHAVIORAL AND CORTICAL RESPONSES

361

B. Kopp, N. Rustamov, R. Rodriguez-Raecke, L. Timm, D. Agrawal, D. Dressler, C. Schrader, P. Tacik, F. Wegner, M. Wittfoth, R. Dengler (Germany)

SENSITIVITY AND SPECIFICITY OF MONTREAL COGNITIVE ASSESSMENT FOR DIAGNOSING MILD NEUROCOGNITIVE IMPAIRMENT IN PD

362

N. Kovács, T. Lucza, Z. Aschermann, S. Komoly, J. Janszky, K. Horvath, K. Kazmer (Hungary)

IS THE MDS-UPDRS A GOOD SCREENING TOOL FOR DETECTING SLEEP PROBLEMS AND DAYTIME SLEEPINESS IN PD? N. Kovács, Z. Aschermann, P. Ács, E. Bosnyák, G. Deli, E. Pál, J. Janszky, B. Faludi, S. Komoly, M. Bokor, E. Rigó, J. Lajtos, P. Klivényi, G. Dibó, L. Vécsi, A. Takáts, A. Tóth, P. Imre, F. Nagy, K. Horváth (Hungary)

60

363


Presentation No.

PREVALENCE OF IMPULSE CONTROL DISORDERS AND OBSESSIVE COMPULSIVE DISORDER IN ELDERLY PATIENTS WITH PARKINSON'S DISEASE.

364

D. Fusco, A.R. Bentivoglio, M.R. Lo Monaco, R. Liperoti, M.C. Cipriani, A. Mautone, R. Bernabei (Italy)

CO-OCCURRENCE OF MILD NEUROCOGNITIVE DISORDER AND DEPRESSION IN PD AFFECTS RECOGNITION OF BOTH NEGATIVE AND POSITIVE FACIAL EMOTIONS

365

I. Laskowska, L. Gawrys (Poland)

CLINICAL PROFILE OF PARKINSON'S DISEASE IN THE GUMEI COMMUNITY OF MINHANG DISTRICT,SHANGHAI

366

K.Y. Liu, Z.H. Gu, Y.Y. Sun, Y.M. Sun, W.Q. Chen, N. Shi, L. Jin, Y. Zhang, J.F. Li, X.J. Sun (China)

PREVALENCE AND PECULIARITIES OF NEUROPSYCHIATRY IN NON-TREATED NON-DEMENTED PD

367

N. Lobjanidze, N. Akiashvili, T. Maisuradze, M. Janelidze, K. Esartia, N. Kvirkvelia (Georgia)

MEDIAL TEMPORAL LOBE AND HIPPOCAMPUS SUBFIELD ATROPHY IS RELATED TO CSF BIOMARKER LEVELS IN EARLY PARKINSON'S DISEASE

368

A.L. Stav, K.K. Johansen, E. Auning, I.S. Almdahl, P. Selnes, A. Bjornerud, D. Aarsland, T. Fladby (Norway)

QUALITATIVE AND QUANTITATIVE ANALYSIS OF ANXIETY PROVOKING SITUATIONS AMONG PATIENTS WITH ESSENTIAL TREMOR

369

L. Hunt, D.A. Lundervold, P.A.A. Ament, P.S. Holt (USA)

TREMOR DISABILITY PREDICTS SUBJECTIVE DISTRESS AND SOCIAL ANXIETY AMONG ESSENTIAL TREMOR PATIENTS370 D. Lundervold, P.A.A. Ament, P.S. Holt (USA)

PREVALENCE OF NON-MOTOR SYMPTOMS AND QUALITY OF LIFE IN PATIENTS WITH PD

371

T. Maeda, T. Shinoda, R. Muraoka, M. Sugawara, Y. Fujimaki, D. Takano, T. Yamazaki, Y. Satoh, K. Nagata (Japan)

A DEDICATED MULTIDISCIPLINARY (MDT) PD SERVICE IN A DISTRICT GENERAL HOSPITAL – OUR EXPERIENCE

372

R. Mappilakkandy, C. Miller, L. Moore, P. Rhead (United Kingdom)

PISA SYNDROME IN PD: DEMOGRAPHIC AND CLINICAL CORRELATIONS IN A MULTICENTER ITALIAN STUDY

373

A. Matinella, C. Geroin, A. Fasano, C. Vitale, M. Canesi, R. Ceravolo, S. Rossi, A. Thomas, G. Fabbrini, A. Bentivoglio, F. Tamma, G. Cossu, A. Pisani, N. Modugno, M. Zappia, M. Volontè, C. Dallocchio, G. Abbruzzese, C. Pacchetti, G. Defazio, F. Morgante, A. Cannas, P. Barone, M. Tinazzi (Italy)

EFFECTS OF SLEEP DISORDERS ON COGNITIVE FUNCTION IN PD

374

R. Matmurodov, M. Raimova, K. Khalimova (Uzbekistan)

COMPARATIVE ASSESSMENT OF NON MOTOR MANIFESTATIONS OF THE PARKINSON’S DISEASE AND VASCULAR PARKINSONISM

375

M. Raimova, R. Matmurodov, K. Khalimova (Uzbekistan)

61


Presentation No.

ANALYSES OF GAIT IN PARKINSON'S DISEASE USING A MOTION CAPTURE SYSTEM

376

M. Menendez-Gonzalez, A. Díaz-Cantalejo, L. Ruíz, H. Olmedillas, R. Ribacoba, A. López-Muñiz, M. Del Valle (Spain)

CLINICAL AND BIOCHEMICAL HETEROGENEITY OF PD

377

I.V. Miliukhina, A. Bernadotte, M.N. Karpenko (Russia)

NEURODEGENERATION AS A NUTRIENT DEFICIENCY SYNDROME

378

L. Mischley (USA)

AWAKE BRUXISM AND PARTICULARITIES OF PHOTIC DRIVING RESPONSE IN ELECTROENCEPHALOGRAPHY: A CASE REPORT.

379

C. Moret Chalmin (France)

EVALUATING THE PSYCHOMETRIC PROPERTIES OF AN ELECTRONIC VERSION OF THE PARKINSON'S DISEASE QUESTIONNAIRE (PDQ-39)

380

D. Morley, S. Dummett, L. Kelly, J. Dawson, C. Jenkinson (United Kingdom)

INPATIENT MANAGEMENT OF PARKINSON’S DISEASE MEDICATION IN NON-ELECTIVE ADMISSIONS- ARE WE DELIVERING MEDICATIONS ON TIME?

381

D. Negin, P. Worth (United Kingdom)

DIAGNOSTIC ACCURACY OF F-18 FP-CIT PET FOR CLINICALLY UNCERTAIN PARKINSONIAN SYNDROME

382

M. Oh, J.S. Kim, J.S. Oh, S.J. Oh, S.J. Lee, S.J. Chung, C.S. Lee (Korea)

COMPARISON OF VESICULAR MONOAMINE TRANSPORTER-2 AMONG SUBSTANTIA NIGRA AND VENTERAL TEGMENTAL AREA

383

H. Omidi, P. Pasbakhsh, N. Omidi (Iran)

MUSICAL HALLUCINATIONS IN PD

384

H. Park, A.R.O. Kim, H. Shin (Korea)

DEMENTIA IN MULTIPLE SYSTEM ATROPHY: IS AMYLOID PATHOLOGY ATTRIBUTABLE?

385

H. Park, H. Shin, J.H. Lee (Korea)

EFFECTIVENESS OF ACUPUNCTURE AND BEE VENOM ACUPUNCTURE ON IDIOPATHIC PD

386

K. Doo, S. Cho, J. Park, C. Ko, S. Park (Korea)

CASE REPORT : TWO SIBLINGS WITH CEREBROTENDINOUS XANTHOMATOSIS

387

M.Y. Park, D.S. Shin (Korea)

NEUROPATHOLOGICAL CHANGES IN THE PDAPPTRANSGENIC MOUSE MODEL OF ALZHEIMERS DISEASE

388

N. Omidi, P. Pasbakhsh, H. Omidi (Iran)

PROMOTION OF REMYELINATION BY ADIPOSE MESENCHYMAL STEM CELL TRANSPLANTATION IN A CUPRIZONE MODEL OF MULTIPLE SCLEROSIS P. Pasbakhsh, A.Z.I.M. Hedayatpour, I.R.A.J. Kashani Ragerdi (Iran)

62

389


Presentation No.

MILD COGNITIVE IMPAIRMENT IN PARKINSON’S DISEASE AND ITS PROGRESSION TO DEMENTIA IN THE DENBIGHSHIRE COHORT AT 16-YEARS.

390

P. Hobson, R.J. Meara (United Kingdom)

MOTOR AND NONMOTOR SYMPTOMS IN PD: 5-YEAR FOLLOW-UP

391

M. Petrovic, E. Stefanova, T. Stojkovic, V. Kostic (Serbia)

VOWEL PERCENTAGE AND PARKINSON’S DISEASE: SPECTRO-ACOUSTIC ANALYSIS OF JOHN PAUL II'S SPEECH

392

M. Pettorino, E. Pellegrino (Italy)

ANTIOXIDANT EFFECTS OF RETIGABINE IN RAT MODEL OF NEUROPATHIC PAIN; INFLUENCE OF NITRIC OXIDE MODULATORS393 R. Pottabathini, A. Kumar, A. Bhatnagar (India)

A NOVEL PARKINSON'S DISEASE PAIN QUESTIONNAIRE (KING'S PD PAIN QUEST): THE PATIENT'S PERSPECTIVE

394

A.M. Rizos, P. Martinez-Martin, S. Pal, C. Carroll, D. Martino, C. Falup-Pecurariu, B. Kessel, A. Todorova, A. Sauerbier, A. Martin, M. Parry, S. Bassi, R. Inniss, L. Perkins, P. Odin, A. Antonini, K. Ray-Chaudhuri, A.N.D. On behalf of EUROPAR and the IPMDS Non motor PD Study Group (United Kingdom)

MRI-BASED CORTICAL THICKNESS AND ITS ASSOCIATION WITH COGNITIVE DYSFUNCTION IN MULTIPLE SYSTEM ATROPHY (MSA)

395

S. Roeske, D. Meiberth, J. Nitsche, K. Schrickel, M. Abele, D. Timmann, U. Wüllner, M. Wagner, K. Amunts, C. Helmstaedter, B. Weber, T. Klockgether, M. Minnerop (Germany)

5 YEARS SURVIVAL AND COGNITIVE AND FUNCTIONAL DECLINE IN DEMENTIA WITH LEWY BODIES AND ALZHEIMER’S DISEASE

396

A. Rongve, M. Breitve, L. Chwiszczuk, H. Soennesyn, R. Skogseth, D. Aarsland (Norway)

A STUDY OF EFFECT OF ISTRADEFYLLINE IN WEARING OFF AND NON-MOTOR SYMPTOMS OF PD PATIENTS

397

H.S. Saiki, S.M. Matsumoto (Japan)

SEROTONERGIC FIBERS PLAY A CRITICAL ROLE IN BOTH DYSKINESIA AND BEHAVIORAL HYPERACTIVITY DRIVEN BY CHRONIC L-DOPA IN NON-HUMAN PRIMATES.

398

L. Tremblay, M. Beaudoin-Gobert, E. Météreau, J. Epinat, S. Duperrier, F. Liger, C. Tourvielle, D. Le Bars, V. Sgambato-Faure (France)

CHARACTERIZATION OF [18F]-2FNQ1P, A PET RADIOTRACER FOR SEROTONIN 5-HT6 RECEPTORS, IN NONHUMAN PRIMATES.

399

V. Sgambato-Faure, S. Fieux, B. Vidal, S. Duperrier, F. Lavenne, N. Costes, D. Le Bars, L. Tremblay, T. Billard, L. Zimmer (France)

HEART RATE VARIABILITY IN PARKINSON’S DISEASE PATIENTS WITH TREMOR-DOMINANT SUBTYPE COMPARED TO AKINETIC-RIGID SUBTYPE.

400

P. Solla, C. Cadeddu, A. Cannas, M. Deidda, C.S. Mulas, G. Mercuro, F. Marrosu (Italy)

SET-SHIFTING DEFICITS IN A PRESYMPTOMATIC BACHD TRANSGENIC RAT MODEL FOR HUNTINGTON’S DISEASE 401 V. Sosti, S. Martínez-Horta, J. Perez-Perez, F. Arenas-Ríos, J. Kulisevsky (Spain) 63


Presentation No.

ASYMMETRICAL AND BILATERAL 6-OHDA LESIONED RATS AS A NEW POTENTIAL MODEL OF PREMOTOR STAGE OF PD

402

V. Sosti, F. Arenas Rios, J. Aguilera, J. Kulisevsky (Spain)

NON MOTOR SYMPTOMS IN PROGRESSIVE SUPRANUCLEAR PALSY

403

F. Stocchi, M. Torti, F.G. Radicati (Italy)

CLIENT SATISFACTION WITH CONTINUOUS INTRA-INTESTINAL INFUSION OF LEVODOPA/CARBIDOPA IN ADVANCED PD

404

A. Tautscher-Basnett, V. Tomantschger, M. Freimueller (Austria)

DOPAMINE TRANSPORTER SPECT PROVIDES INSTRUMENTAL DIAGNOSIS OF AKINETIC CRISIS OF PARKINSONISM AND OF NEUROLEPTIC MALIGNANT SYNDROME

405

G. Martino, M. Capasso, M. Nasuti, L. Bonanni, M. Onofrj, A. Thomas (Italy)

"HARD TO SWALLOW" A SINGLE-CASE STUDY OF A PATIENT WITH ADVANCED PD WHO RECOVERED FROM TOTAL DYSPHAGIA

406

V. Tomantschger, A. Tautscher-Basnett, E. Striedinger, C. Seitner-Stadik, M. Freimueller (Austria)

EXPIRATORY MUSCLE STRENGTH TRAINING CAN IMPROVE HYPOKINETIC DYSARTHRIA IN PD AND PROGRESSIVE SUPRANUCLEAR PALSY.

407

S. Tomita, T. Oeda, A. Umemura, M. Kohsaka, R. Hayashi, K. Park, K. Yamamoto, H. Sugiyama, H. Sawada (Japan)

NON-MOTOR MANIFESTATIONS OF PARKINSONISM IN MPTP-TREATED MICE AND IN PATIENTS

408

M. Ugrumov, R. Nigmatullina, V. Kovalzon, V. Kudrin, Z. Zalyalova, T. Pronina (Russia)

MECHANISMS OF SLEEP PATTERNS DISRUPTION IN A FLY MODEL OF PD

409

J.S. Valadas, G. Esposito, P. Verstreken (Belgium)

LONG-TERM OUTCOMES FOR PD PATIENTS WITH NORMAL COGNITION

410

K. Pigott, J. Rick, H. Hurtig, A. Chen-Plotkin, J. Duda, J. Morley, L. Chahine, N. Dahodwala, J. Fleisher, R. Akhtar, S. Xie, J.O.H.N. Trojanowski, D. Weintraub (USA)

DECREASED BURDEN AMONG CAREGIVERS OF PATIENTS WITH PD PSYCHOSIS (PDP) TREATED WITH PIMAVANSERIN, A SELECTIVE 5-HT2A ANTAGONIST

411

D. Aarsland, R. Mills, H. Williams, K. Chi-Burris, M. Karistedt, C. Ballard (Sweden)

UP-REGULATION OF ROS-DEPENDENT MMP-9 FROM HIGH GLUCOSE-CHALLENGED ASTROCYTES CONTRIBUTES TO THE NEURONAL APOPTOSIS

412

C. Yang, P.C. Chi (Taiwan)

MICROBLEEDS ARE ASSOCIATED WITH INCREASED RISK OF DEMENTIA IN PATIENTS WITH PD

413

J. Yoon, M. Lee, I. Joo, K. Huh (Korea)

DETERMINANTS OF COGNITIVE THEORY OF MIND IN PD R.L. Yu, R.M. Wu (Taiwan)

64

414


Presentation No.

THE EFFECT OF ELECTROCONVULSIVE THERAPY ON PSYCHIATRIC SYMPTOMS OF DEMENTIA WITH LEWY BODIES (DLB)

415

K. Matsuoka, F. Yasuno, H. Hasegawa, Y. Yamaguchi, M. Takahashi, K. Kiuchi, K. Hashimoto, T. Kishimoto (Japan)

65

Practice-changing content, expert opinion, and trusted perspective

The Lancet Neurology is the leading clinical neurology journal, delivering essential original research, expert review, candid commentary, and timely news to provide context and perspective on important advances in clinical neurology. Our goal is to publish only the highest quality content with relevance to clinical decision-making. We are committed to rapid dissemination of our research with fast-track publication within 8 weeks of submission. With an Impact Factor of 21·823, we rank first among all clinical neurology journals.

Gain greater insight and stay well-informed about the global clinical neurology community with The Lancet Neurology’s resources. • • • • •

Essential, high impact research and reviews Expert commentary and breaking news Free eToC and news alerts Free monthly podcasts featuring renowned authors Specially commissioned Series and reports, many of which are freely available • The Lancet iPad app for 24/7 access

www.thelancet.com/neurology THE LANCET® is a registered trademark of Reed Elsevier Properties SA, used under licence.

The index is an alphabetical listing of names of speakers, session chairs and abstract authors and co-authors involved in the Scientific Program. The Presentation Number refers to the sequence in which their presentation appears in the program. These numbers are in sequential order and can be seen on the right of each presentation in the Scientific Program. This Presentation Number is not a page number. You are able to locate the speaker by presentation number in the Scientific Pages.

www.kenes.com/nmdpd

INDEX OF


Aarsland, D.

126, 166, 285, 309, 342, 368, 396, 411

Abbruzzese, G.

373

Abele, M.

395

Ács, P.

335, 337, 363

Adams, S.

316

Adrien, J.

144

Agarwal, V.

277

Agarwal, V.A.

34

Agid, Y.

2, 3, 10

Agrawal, D.

361

Aguilera, J.

402

Ahmed, B.

259

Ahmed, R.

132

Ahn, T.B.

318

Akhtar, R.

410

Akiashvili, N.

367

Al Harraq, Z.

260

Al-Rejaie, S.

132

Al-Samhari, M.

132

Albani, G.

281

Albin, R.L.

269

Alcalay, R.

71, 74

Alinegad, M.

330

Almdahl, I.S.

368

Alrasheed, N.

132

Álvarez-Avellón, T.

262

Ament, P.

253

Ament, P.A.A.

369, 370

Aminov, K.

326, 328

Amunts, K.

395

Antier, E.

146

Antonini, A.

7, 35, 119, 236, 263, 283, 394

Aoki, N.

297

Arab, A.

46

Arbelo, J.M.

274

Arenas Rios, F.

402

Arenas-Ríos, F.

401

Arnaldi, D.

213

Arnulf, I.

144, 343

Aronsson, P.

340

Benesh, J.

295

Asatryan, S.

345

Bensafi, M.

292

Asayama, S.

56, 351

Bentivoglio, A.

373

Aschermann, Z.

335, 337, 362, 363

Bentivoglio, A.R.

364

Ashkan, K.

117

Benyakov, O.

70

Ashrafi, F.

322, 324

Berendse, H.W.

211

Aubert, C.

264

268

Auburger, G.

323

BerghauzenMaciejewska, K.

Auning, E.

368

Bergmann, L.

35

Bergquist, F.

340

Bernabei, R.

364

Bernadotte, A.

377

Berto, P.

263

Bertolucci, P.H.F.

15

Bertoni, S.

260

Beudin, P.

308, 313

Bhatia, K.

148

Bhatnagar, A.

393

Bhattacharyya, K.

47

Bhattacharyya, K.B.

81

Billard, T.

399

Biswas, A.

81

Biundo, R.

283

Bjornerud, A.

368

Blanc, F.

342

Blandini, F.

260

Bleuse, S.

182

Boel, J.A.

85

Boeve, B.

285

Bohnen, N.

111

Bohnen, N.I.

269

Bokor, M.

363

Avetisyan, A.Y. Avila, S. Azulay, J. Azulay, J.P. Babiloni, C. Balash, Y. Ballabeni, V. Ballard, C. Banafshe, H.R. Bandegani, N. Bandres, S. Bangma, D. Bangma, D.F.

133 316 6, 226, 228 286 244 301, 317 260 411 330 324 266 252 83

Barbosa, E.R.

57

Barocelli, E.

260

Barone, P.

235, 373

Barrero, F.J. Bassi, S. Bastos Lima, A. Baunez, C. Bayulkem, K.

266 394 303 155 147

Beaudoin-Gobert, M.

398

Bedetti, C.

270

Bonanni, L.

405

Beekharee, D.

145

Bondarenko, A.

131

Beeler, J.A.

174

Bonizzoni, E.

275

Belaid, H.

144

Bonnani, L.

342

Belarbi, K.

145, 182

Booij, J.

211

Benazzouz, A.

88, 201

Boraud, T.

264

Benchetrit, E.

293

Borg, M.A.

53

Bencsik, A.

146

Borghammer, P.

45, 310

69

70

Bosnyák, E.

363

Chahine, L.

410

Clark, S.

144

Bougea, A.

17

Chan, K.

69

Coletto, E.

143

Boulinguez, P.

60, 257

Chan, K.A.H.O.

69

Collett, J.

37

Bourbouli, M.

17

Chan, L.L.

278

Colman, K.S.F.

83

Bousleiman, H.

24, 25, 86

Chao, Y.H.

282

Compta, Y.

199

Boyko, E.V.

298

182

Comptdaer, T.

182, 290

Brehm, N.

323

Chartier-Harlin, M.-C.

Compton, M.

253

Breitve, M.

285, 396

Chartier-Harlin, M.C.

145, 146, 290

Coppola, G.

198

Brice, A.

72, 343

Chatamra, K.

295

Cordone, S.

244

Bronner, G.

214, 218

Chaturvedi, M.

24, 86

Cormier, F.

343

Brooks, D.J.

45, 195

Chaudhuri, K.

49,255

Corvol, J.C.

75, 293, 343

Brousolle, E.

11, 52

Chaudhuri, K.R.

143

Cossu, G.

373

Broussolle, E.

156

Chen, J.

291

Costes, N.

399

Bruneau, M.A.

270

Chen, L.

69

Coulibaly, T.

287

Buated, W.

339

Chen, W.Q.

299, 366

Coulibaly, T.H.

287

Bucks, R.S.

26

Chen-Plotkin, A.

410

Cras, P.M.

67

Buklina, S.

131

Cheon, S.M.

355

Cronin-Golomb, A.

350

Burn, D.

134

Cherninskyi, A.O.

250

Cubo, E.

274

Burn, D.J.

85, 121

Chesselet, M.F.

140, 142

Cuetos Vega, F.

262

Cadeddu, C.

400

Chetsawang, B.

265

Czernecki, V.

137

Caillet-Boudin, M.L.

290

Chi, P.C.

412

Dabrowska, M.

84

Calabrese, P.

185, 239, 242

Chi-Burris, K.

411

Dagher, A.

175

Campo, M.

283

Cho, J.

338

Dahodwala, N.

410

Canesi, M.

271, 373

Cho, J.W.

186

Dallocchio, C.

373

Cannas, A.

373, 400

Cho, K.

321

Damásio, J.

303

Cho, S.

386

Damier, P.

101, 127

Choi, H.

188

Daneault, J.

92

Choi, J.

279

Daneault, J.F.

296

Choudhry, A.

280

Danielsen, E.H.

45

Chouinard, S.

270

Das, D.

81

Chraa, M.

276

Davatzikos, C.

269

Chua, K.

69

Dawes, H.

37

Chung, S.

284

Dawson, J.

380

Chung, S.J.

354, 356, 382

de Baat, C.

38

Chwiszczuk, L.

396

de Bie, R.M.A.

115

Chwiszczuk, L.J.

285

de Broucker, A.

182, 290

Cicolin, A.

313

de Deyn, P.P.

18

Cipriani, M.C.

364

de Jong, B.M.

18

Cisse, L.

287

de Pedro-Cuesta, J.

54

Clare, L.

80

de Silva, V.A.

288

Capasso, M.

405

Carlsson, T.

340

Caron, E.

145

Carroll, C.

394

Carron, R.

286

Casares, C.T.

315

Catalan, M.J.

289, 274

Cattaneo, C.

275

Cattani, L.

281

Cavaco, S.

303

Ceravolo, R.

373

Cerri, S.

260

Chabardes, S.

13, 156

Chadahidi, A.

221

Chahidi, A.

276

Debilly, B.

313

Durán, R.

266

Fasano, A.

373

Defazio, G.

222, 373

Durif, F.

129, 162, 308, 313

Fedorova, T.

45, 310

Degroot, C.

270

Dutkiewicz, J.

205

Fengler, S.

252

Deidda, M.

400

Duval, C.

92, 296

244

Dynin, P.S.

298

Fereshtehnejad, S.M.

267

Del Percio, C. del Valle, M.

376

Dzimiri, N.

132

Fernagut, P.

77

Fernagut, P.O.

163

Ferri, R.

308

Fieux, S.

399

Figeac, M.

182, 290

Figorilli, M.

308, 313

Fiorenzato, E.

283

Fladby, T.

309, 342, 368

Fleisher, J.

410

Fluchčre, F.

249, 286

Fonoff, E.

42, 57

Fonoff, F.M.C.

57

Forjaz, M.

54

Forsgren, F.

294

Foster, P.S.

325

Fournel, A.

292

Francois, C.

144

Franssen, M.

37

Freimueller, M.

404, 406

Frey, K.A.

269

Friedman, A.

202, 205

Frisoni, G.B.

244

Fuentes, D.C.

57

Fuhr, F.

24

Fuhr, P.

19, 20, 23, 25, 86, 243, 244

Fujimaki, Y.

371

Fujinami, T.

339

Fujita, K.

56, 351

Fukushima, T.

312

Fusco, D.

364

Gabillon, E.

264

Gaig, C.

199

Gamaleya, A.

131

Gambini, F.

263, 275

Gangadharan, S.

16

Delaville, C. Delbari, A. Deli, G. Demay, C. Dembele, K. Deng, M. Dengler, R. Denning, Y. Derkinderen, P. Derost, P. Destee, A. Diamantoudi, M. Díaz-Cantalejo, A. Dibó, G. Dickson, D. Dierckx, R.A.

201 267 335, 337, 363 182 287 291 361 146 179 313 141, 145, 182, 290 341 376 190, 307, 363 297 18

Eaton, S. Ebrahimi, A. Ebrahimi, H. Ebrahimi, S. Eccles, F.J.R. Edelstyn, N. Edelstyn, N.M.J. Edwards, J. Ehrminger, M. El Assawy, N. El-Hawary, M. Elboum, L. Elgh, E. Ellgring, H. Ellis, S.J. Ellis, T.D.

295 300 300 332 331 82 79 245 343 281 261 319 294 315 79, 82 350

Dimitrov, N.

304

Elsinga, P.H.

18

Djordjevic, J.

292

Emmanouilidou, E.

17

Dlotko, E.

263

Epinat, J.

398

Doletschek, C. Domellöf, . Domenichini, G. Doo, K.

55 294 260 386

Erdogan, N. Esartia, K. Esposito, G. Estevo Dias, A.

302 367 409 305

Drago, V.

325

Eusebio, A.

286

Drazanova, E.

46

Ezra, A.

301

Dressler, D.

361

Fabbrini, G.

373

Dubernat, A.

264

Faggiani, E.

201

Dubois, B.

96, 135

Faludi, B.

363

Dubow, J.

295

Falup-Pecurariu, C.

29, 394

Duda, J.

110, 410

Fantini, M.

313

Duda, J.E.

106, 167

Fantini, M.L.

308

Dulski, J.

84

Farnaud, S.

259

Dummett, S.

380

Farombi, T.

306

Duperrier, S.

398, 399

Farrall, A.J.

341

71

Gao, S.

291

Guekht, A.

171, 194

Holt, P.

253

García-Rodriguez, B.

315

Guinto, C.O.

287

Holt, P.S.

369, 370

Gasser, A.

185

Gujar, A.

259

Hong, J.P.

354

Gasson, N.

26

Gurevich, T.

85

365

62, 248, 301, 317, 319

Hoogland, J.

Gawrys, L.

Hopes, L.

182

Geary, M.

316

Horvath, K.

362, 363

Gelpi, E.

94, 199

Horváth, R.

335, 337

Gentile, G.

283

Hossein zadeh, A.

300

Geroin, C.

373

Howard, M.

259

Gerritsen, M.J.J.

18

Hsieh, M.

269

Gesquičre-Dando, A.

286

Huh, K.

413

Geurtsen, G.J.

85

Huh, Y.

338

Gevorgyan, E.M.

133

Hunt, L.

369

Giladi, N.

301

Huot, P.

173

Gilat, M.

90

Hurter, H.

24

Gimadutdinov, R.F.

298

Hurter, M.

86

Gimoyan, L.

333, 345

Hurtig, H.

410

Gispert, S.

323

Husnain, O.

259

Gjerlřff, T.

45

Hutter-paier, B.

46

Gjerstad, M.

285

Hynninen, M.J.

285

Gjerstad, M.D.

105

Iida, S.

56

Glowacka, U.

268

Imre, P.

363

Gnudi, G.

260

Inniss, R.

28, 394

Goldman, J.G.

85, 192

Iranzo, A.

104

Goldstein, D.S.

61, 258

Isaacson, S.

349

Gonçalves, A.

303

Isaeva, G.E.

298

Gonce, M.

5

Ishikawa, K.

329

Gorritz, M.

263

Itani, K.

56

Govitrapong, P.

Ivanenko, O.V.

250

Hadinia, A.

23

Haehner, A.

108

Haga, K.

341

Hall, C.

295

Hall, J.M.

90, 336

Hambardzumyan, H.D.

187

Han, H.

320

Hanganu, A.

270

Hanwella, R.

288

Harutyunyan, A.S.

133

Hasbroucq, T.

249

Hasegawa, H.

415

Hashimoto, K.

415

Hassanzadeh, K.

332

Hassin-Baer, S.

191, 216

Hattori, N.

109, 118, 329

Hatz, F.

24, 25, 86

Hauptmann, B.

327

Hauser, R.

280

Havas, D.

46

Hayakawa, T.

312

Hayashi, R.

251, 359, 407

265

Hedayatpour, A.Z.I.M.

389

Grabli, D.

144

Helmstaedter, C.

395

Izadpanah, E.

332

Gray, A.M.

331

Hernandez, I.

199

Jackson, M.J.

143

Gregoric Kramberger, M.

130, 346

Herreros, J.

274

Jakobsen, S.

45 367

145

312

Janelidze, M.

Gressier, B.

Hidaka, T.

348

196

143

Jang, W.

Grinberg, L.

Hikima, A.

362, 363

50, 63, 198

80, 136

Janszky, J.

Grinberg, L.T.

Hindle, J.V.

314

24

329

Januário, C.

Gschwandtner, G.

Hirano, K.

350

19, 20, 25, 86, 244, 23, 240

93

Jaywant, A.

Gschwandtner, U.

Hirayama, M. Hirsch, E.C.

144

Jenkinson, C.

380

Hobson, P.

390

Jenner, P.

143

Hollinde, D.L.

327

Jennum, P.

103

Gu, Z.H. Guedj, E.

72

366 286

Jeon, B.

169

Kim, A.R.O.

384

Konkel, A.

84

Jin, L.

299, 366

Kim, D.A.

89

Konstantinides, V.C.

17

Johansen, K.K.

368

Kim, H.J.

354

Kopp, B.

361

John, C.A.

358

Kim, H.K.

89

Korczyn, A.

1, 4, 51, 317

Jones, S.

136

Kim, J.

Kostic, V.

8, 229, 391

Joo, I.

413

188, 272, 284, 321, 354, 356

Kotagal, V.

269

Joo, J.

320

Kovács, N.

335, 337, 362, 363

Joussain, P.

292

Kovalzon, V.

408

Jurado, R.

315

Krack, P.

113, 125, 156, 157

Kakamu, T.

312

Kraepelien, M.

43

Kalbe, E.

185

Kramberger, M.

342

Kaldo, V.

43

Kreisler, A.

182

Kállai, J.

307, 335, 337

Kryzhanovskyi, S.A.

250

Kanda, H.

312

Kucerova, J.

46

Kaneko, S.

56, 351

Kudlicka, A.

80

Kapaki, E.

17

Kudrin, V.

408

Karachi, C.

144, 154

Kulisevsky, J.

97, 401, 402

Karádi, K.

335, 337

Kulkantrakorn, K.

44

Karagiorga, V.

17

Kumagai, T.

312

Karambe, M.

287

Kumar, A.

41, 393

Karapetyan, A.H.

133

Kumar, P.

282, 358

Karasevich, N.V.

250

Kusaka, H.

56, 351

Karistedt, M.

411

Kuter, K.

268

Karpenko, M.N.

377

Kvirkvelia, N.

367

Karydas, A.

198

Kwon, Y.N.

318

Lacomblez, L.

293

Laffrat, E.

144

Lafontaine, A.L.

270

Lagarde, J.

96

Lajtos, J.

307, 363

Lange, K.W.

83

Larsen, J.

100

Laskowska, I.

365

Latta, P.

46

Lau, Y.

69

Lavenne, F.

399

Lazzeri, G.

263

Le Bars, D.

398, 399

Le Ber, I.

99

Le, W.

33

Kim, J.H.

89

Kim, J.S.

186, 382

Kim, J.W.

355

Kim, K.

284

Kim, K.J.

354, 356

Kim, M.

284

Kim, M.S.

354

Kim, S.O.

354

Kim, Y.

284

Kim, Y.E.

169

Kiriyama, T.

311

Kishimoto, T.

415

Kissani, N.

276

Kita, Y.

311

Kiuchi, K.

415

Klingelhoefer, L.

357

Klinger, H.

156

Klivényi, P.

363

Klockgether, T.

395

Klostermann, F.

55

Kluj-Kozlowska, K.

84

Kashani Ragerdi, I.R.A.J.

389

Kashihara, K.

93, 352

Knaani, J.

317

Kashyap, N.

339

Knudsen, C.S.

310

Kataoka, H.

311

Knudsen, K.

45

Kayabasi, U.

353

Ko, C.

386

Kazmer, K.

362

Koeppe, R.A.

269

Kelly, L.

380

Koerts, J.

83,197, 252

Kerckhofs, E.

67

Koga, S.

297

Kern, B.

323

koh, Y.

358

Kessel, B.

394

Kohsaka, M.

251, 359, 407

Kessler, J.

185

Kolcheva, J.

360

Ketharanathan, T.

288

Koller, V.

327

Khairnar, A.

46

Komoly, S.

335, 337, 362, 363

Khalimova, K.

374, 375

Konate, M.

287

73

Leboidre, M.

146

Lřvli Stav, A.

309

Meara, R.J.

390

Lee, C.S.

382

Lucza, T.

335, 337, 362

Meiberth, D.

395

Lee, D.K.

318

Lundervold, D.

253, 370

Mejia-Constain, B.

270

Lee, J.

279

Lundervold, D.A.

369

Meles, S.K.

18

Lee, J.H.

385

Luo, Y.

312

Melvin, E.

344

Lee, K.

188

Machado, F.C.

15

Memari, M.

300

Lee, M.

413

Maeda, T.

93, 352, 371

Mendes, A.

303

Lee, S.J.

382

Magen, I.

142

262, 376

Lehericy, S.

209

Maiga, B.B.

287

Menendez-Gonzalez, M.

Lemstra, E.

342

Maisuradze, T.

367

Mequinion, M.

145

Mercuro, G.

400

Mertens, P.

156

Mesdaghinia, A.

330

Météreau, E.

398

Meyer, A.

19, 20, 23

Mian, O.

281

Miduri, F.

260

Miliukhina, I.V.

377

Miller, B.L.

198

Miller, C.

91, 372

Miller, N.

204

Mills, R.

411

Minato, T.

93

Minnerop, M.

395

Mir, P.

274

Mischley, L.

378

Mishra, J.

41

Misirli, H.

302

Mitra, R.

340

Moazzezi, S.A.M.

322, 324

Modugno, N.

373

Mok, V.

69

Mokhtari, R.

330

Molina, J.A.

315

Mollenhauer, B.

102, 181, 247, 342

Monchi, O.

227, 232, 270

Montero, H.

31

Montero, P.

274

Moore, L.

372

Moradiya, V.

259

Leprętre, F. Leu-Semenescu, S. Levandis, G. Levy, R. Lewis, S.J.G. Lhommée, E. Li, J.F. Li, M.I.N. Li, X. Liger, F. Lindefors, N. Liperoti, R.

343 260 96, 124 90, 336 156 299, 366 69 291 398 43 364

Mallone, M. Mamikonyan, E. Manor, Y. Manso-Calderón, R. Manvelyan, H.M. Mappilakkandy, R. Marcon, V. Marien, P. Marin, S.M.C. Marques, A. Marrosu, F. Marti, M.J.

281 344 319 273 133, 187 91, 372 283 67 15 308, 313 400 199

Lister, J.

263

Martin, A.

28, 357, 394

Litvan, I.

85

Martinez Martin, P.

219, 241

Litvinenko, I.V.

298

Martínez-Horta, S.

401

Liu, K.Y. Liu, W.E.I. Liu, X. Lizio, R. Lo Monaco, M.R. Lobjanidze, N. Loftus, A.M. Lökk, J. Lolekha, P. Londos, E. Lopez, G. Lopez, S. López-Muńiz, A. Lopiano, L. Loundou, A.

74

182, 290

299, 366 32 291 244 364 367 26 267 44 342 76 244 376 313 286

Martinez-Martin, P. Martino, D. Martino, G. Marzano, N. Marzinzik, F. Matinella, A. Matmurodov, R. Matsumoto, S.M. Matsuoka, K. Matthews, J. Mauro, A. Mautone, A. Mayes, A.R. McDowell, K. McKeith, I.

54, 274, 394 357, 394 405 244 55 373 374, 375 397 415 316 281 364 82 142 120

Morales, I.

315

Nexo, E.

310

Morbelli, S.

213

Ng, E.

282

Moreira, F.

314

Ng, K.M.

278

Moreira, I. Moret Chalmin, C. Morgadinho, A. Morgante, F. Mori, Y. Morley, D. Morley, J. Moroni, F. Morya, E. Mouridsen, K. Moustafa, A.A. Mowszowski, L. Mróz, B. Mulas, C.S. Muller, A.J. Muller, M. Muller, M.M. Muraoka, R. Murray, M.

303 21, 379 314 373 312 380 410 271 42 310 336 90 268 400 336 107, 111 269 371 297

Nicolelis, M. Nigmatullina, R. Nitsche, J. Nkiliza, A. Nobili, F. Noce, G. Nomura, T. Nowalk, N. O’Callaghan, C. Ocepek, L. Odin, P. Oeda, T. Ogunniyi, A. Oh, J.E. Oh, J.S. Oh, M. Oh, S.J. Oh, Y. Okada, Y.

42 408 395 182 213 244 352 316 90, 336 130 203, 207, 394 251, 359, 407 306 89 382 382 382 188 311

Murray, M.E.

200

Okai, D.

161

Mutez, E.

182

Oki, M.

56, 351

Naasan, G.

198

Okun, M.

116

Nagashima, M. Nagata, K. Nagy, F. Nahimi, A. Naismith, S.L. Nakamura, J. Nakamura, M. Narita, N. Narozanska, E. Nasuti, M. Navarro-Otano, J. Negin, D. Negrotti, A. Neumann, L. Neumann, M.

56, 351 371 363 45 90 311 56, 351 347 84 405 199 381 128 253 98

Oliveira, F.F. Olmedillas, H. Omidi, H. Omidi, N. Onofrj, M. Oryan, S. Ossowska, K. Owolabi, M. Pacchetti, C. Padmakumar, C. Pagonabarraga, J. Pál, E. Pal, S. Pan-Montojo, F. Panisset, M.

15 376 383, 388 383, 388 405 332 268 306 373 16 97 363 394 12, 146 292

Papaterra Limongi, J.

305

Parameyong, A.

265

Paraskevas, G.

17

Parent, M.

172

Parizel, P.M.

67

Park, H.

188, 279, 384, 385

Park, I.

188

Park, J.

338, 386

Park, J.K.

186

Park, K.

251, 359, 407

Park, K.H.

89

Park, M.

272

Park, M.Y.

14, 387

Park, O.T.

89

Park, S.

68, 386

Parra, J.

289

Parry, M.

304, 394

Pasbakhsh, P.

383, 388, 389

Patel, K.

259

Pavese, N.

45

Pelegrina, J.

266

Pellegrino, E.

392

Peretz, C.

301

Perez Lloret, S.

225

Perez-Perez, J.

401

Perkins, L.

28, 394

Perret-Liaudet, A.

177

Petit, E.

264

Petrou, M.

269

Petrovic, M.

39, 391

Pettorino, M.

392

Pezzoli, G.

271

Phillips, J.

336

Picco, A.

213

Pickut, B.

67

Pigott, K.

410

Pineau, F.

293

Pirtosek, Z.

66, 130, 346

Pisani, A.

373

75

76

Poewe, W.

35

Rick, J.

410

Santos, D.

289

Pollak, P.

153, 156

Rigó, E.

363

Sardina, M.

263, 275

Posen, J.

319

Riley, B.

334

Satoh, Y.

371

Pottabathini, R.

393

Rizos, A.

357

Sauerbier, A.

22, 27, 394

Pourcher, E.

170

Rizos, A.M.

394

Saunders, E.

27

Priba, M.

198

Roberts, H.C.

34, 277

Sawada, H.

251, 359, 407

Pronina, T.

408

Robowski, P.

84

Schindlbeck, K.

55

Puligheddu, M.

308, 313

54

Schinwelski, M.

84

Pushpanathan, M.

26

Rodriguez-Blazquez, C.

Schlesinger, I.

65, 70

Quaranta, T.

57

361

Schmand, B.A.

85

Radicati, F.G.

403

Rodriguez-Raecke, R.

332

323

361

Rahimmi, A.

Roeper, J.

Schrader, C.

81

395

395

Rai, S.

Roeske, S.

Schrickel, K.

374, 375

285, 396

146

Raimova, M.

Rongve, A.

Schwarz, M.

130

95, 150

331

Rajnar, R.

Rosales, R.

Scott, R.B.

261

314

198

Rakha, M.

Rosário Almeida, M.

Seeley, W.W.

266

143

323

Ramírez, M.

Rose, S.

Seidel, K.

271

373

406

Ranghetti, A.

Rossi, S.

Seitner-Stadik, C.

220, 224

185

368

Rascol, O.

Rossier, P.

Selnes, P.

282

81

182, 290

Ratnagopal, P.

Roy, A.

Semaille, P.

319

301

81

Rauf, O.

Rozenberg, A.

Senapati, A.K.

176, 180

307

353

Ravid, R.

Rózsa, S.

Sergott, R.

27, 35, 54, 304, 357

323

398, 399

Ray Chaudhuri, K.

Rüb, U.

Sgambato-Faure, V.

Rubio, G.

315

Shabalov, V.

131

Ruíz, L.

376

Shafieisabet, M.

267

Rumpel, H.

278

Shahidi, G.A.

267

Rusconi, M.L.

271

Sharma, N.

41

Rustamov, N.

361

Shepherd, T.

79

Ryu, H.J.

355

Shepherd, T.A.

82

Saadatnia, M.

300

Sherman, S.

263

Sadikot, A.

292

Shi, N.

299, 366

Sadikot, A.F.

92, 296

Shin, D.

320

Saiki, H.S.

397

Shin, D.S.

387

Saiki, S.

329

Shin, H.

384, 385

Saito, A.

56, 351

Shinagawa, S.

198

Saitoski, K.

145

Shine, J.M.

90, 336

Salama, M.

261

Shinoda, T.

371

Sameshima, K.

42

Shohei, H.

339

Sampaio, G.

15

Shomoto, K.

311

Sihotra, S.

259

Silvanyan, G.

333, 345

Ray-Chaudhuri, K.

28, 394

Rees, M.

16

Regidor, I.

289

Régis, J.

286

Reichmann, H.

12

Reis Barbosa, E.

305

Rektor, I.

233, 237

Rektorova, I.

9, 46, 231

Relja, M.

234

Rewitzer, C.

55

Rey, M.J.

199

Reynaud, A.

264

Rhead, P.

372

Ribacoba Montero, R.

262

Ribacoba, R.

376

Samuel, M.

112, 158, 159

Ribalta, T.

199

Sang-Myung, C.

272

Simonin, C.

182

Svenningsson, P.

43, 178

Treves, T.

123

Sissoko, A.S.

287

Swe, S.T.P.

358

410

Sitek, E.

84

Szeto, J.Y.Y.

90

Trojanowski, J.O.H.N.

Sixel-Döring, F.

102

Tache, Y.

58

Trojanowski, J.Q.

198

Trost, M.

130

Tröster, A.I.

85

Truong, D.

151, 246

Tse, K.

69

Tsuboi, Y.

352

Tsuge, A.

56, 351

Tsuji, M.

312

Tsuji, S.

64

Tu Hsing, W.

305

Tucha, L.

83, 252

Tucha, O.

83, 252

Tunali, F.

302

Ueno, S.

311

Ugrumov, M.

408

Skogseth, R. Slawek, J. Smrdu, M. So, H.Y. Sobh, M. Socha, J. Soennesyn, H. Soland, V. Solla, P. Soltan, W. Song, J. Sosti, V. Spikman, J.M. Stack, E. Stack, E.L. Stafford, R. Stamelou, M. Starcuk jr, Z.

396 30, 84, 238 346 354 261 293 396 270 400 84 312 401, 402 18 277 34 259 149 46

Stav, A.L.

368

Stefanova, E.

139, 183, 391

Stieglitz, R.D.

20, 23

Stievenard, A.

145, 146, 182

Stocchi, F.

215, 217, 403

Stojkovic, T.

391

Strafella, A.

230

Striedinger, E.

406

Sturzenegger, R.

24, 86

Suarez del Chiaro, I.

249

Subramanian, L.

136

Sugawara, M.

371

Sugiyama, H.

251, 359, 407

Suh, M.

338

Sulcova, A.

46

Sun, X.J.

299, 366

Sun, Y.M.

299, 366

Sun, Y.Y.

299, 366

Tacik, P. Taillieu, D. Takahashi, M. Takano, D. Takáts, A. Takeda, A. Takenouchi, N. Tamma, F. Tan, E. Tan, E.K. Tan, X. Tandé, D.

361 145 415 371 363 78 56, 351 373 165 168, 278, 282, 358 312 144

Tautscher-Basnett, A.

404, 406

Teixeira, M.J.

42, 57

Ulla, M.

313

Thobois, S.

87, 156

Umemura, A.

251, 359, 407

Thomas, A.

373, 405

Valadas, J.S.

409

Thomas, M.G.

26

Valldeoriola, F.

199

Timm, L.

361

211

Timmann, D.

395

van den Heuvel, O.A.

Timmermann, L.

114

van der Boon, W.M.

38

van der Zee, S.

18

Van Hecke, W.

67

van Laar, T.

18

van Steenoven, I.

342

van Stiphout, M.A.E.

38

Vanbesien, C.

146

Vanbesien-Mailliot, C.

145

Tinazzi, M. Tobin, G. Todorova, A. Tolosa, E.

223, 373 340 304, 394 199

Tomantschger, V.

404, 406

Tomita, S.

251, 359, 407

Tomskiy, A.

131

Torti, M.

403

Tóth, A.

363 254

Vanbesien-Mailliot, C.-C.

182

Touchon, J. Tourvielle, C.

398

Vanneste, S.

67

287

Varescon, I.

293

102

Vecsei, L.

40, 256, 307

Tremblay, L.

398, 399

Vécsi, L.

363

Trenkwalder, C.

102

Vegezzi, G.

260

Vekrelis, C.

17

Traore, M. Trautmann, E.

77

Verin, M.

184, 138

Verstreken, P.

409

Vidailhet, M.

48, 152, 343

Vidal, B.

399

Vidal, T.

313

Vila-Chă, N.

303

Villemagne, V.L.

212

Viltart, O.

145

Vinci, C.

281

Vitale, C.

373

Vitello, N.

313

Vives, F.

266

Volontč, M.

373

Voon, V.

193

Wagner, M.

395

Wajman, J.R.

15

Walker, Z.

208, 210

Walter, M.

323

Walton, C.C.

90, 336

Wang, P.

312

Wardas, J.

78

268

Wate, R.

56, 351

Watts, K.

79

Weber, B.

395

Weerasundera, R.

288

Wegner, F.

361

Weil, J.

323

Weintraub, D.

54, 122, 160, 164, 189, 280, 342, 344, 410

Weintraut, R.

335, 337

Weis, L.

283

Wieczorek, D.

84

Wiesli, D.

19

Williams, H.

411

Williams-Gray, C.H.

73

Winder, M.

340

Windisch, M.

46

Withanage, A.

16

Witjas, T.

286

Wittfoth, M.

361

Woitalla, D.

59, 206

Worth, P.

381

Wu, R.M.

414

Wüllner, U.

395

Xie, S.

344, 410

Yamaguchi, Y.

415

Yamamoto, K.

251, 359, 407

Yamazaki, T.

371

Yang, C.

412

Yang, D.

188

Yasuno, F.

415

Yegin, A.

35

Yeoh, C.S.

278

Yoon, J.

413

You, S.

284

Youn, J.Y.

186

Yu, R.L.

414

Yurin, A.A.

298

Zablith, I.

293

Zali, A.

322, 324

Zalyalova, Z.

408

Zappia, M.

373

zarghi, A.

322, 324

Zella, S.

206

Zhang, X.

36

Zhang, Y.

299, 366

Zhao, Y.

358

Zheng, L.

32

Zhu, J.

32, 36

Zibetti, M.

313

Zimmer, L.

399

Zimmermann, R.

19, 20, 23, 24, 25, 86

Zlotnik, Y.

301

Zupancic Kriznar, N.

130

Zyma, I.G.

250

www.kenes.com/nmdpd

RECOGNITION, ACKNOWLEDGEMEN AND INDUSTRY

Parkinson’s Disease in the advanced stage: It´s a dire existence. It´s odd. Really. Caught in a cage of stiffness and unability. Dacepton® gets them back to life. As the strongest non selective dopamine agonist, Dacepton® shortens the „off“-phases1 and reduces the intensity of dyskinesias2. Dacepton® is the therapy with continuous dopaminergic stimulation for advanced Parkinson‘s disease via subcutaneous infusion. 1) Gunzler, 2009, 2) Kanovsky et al., 2002

ACKNOWLEDGEMENTS The Organizing Committee of The 10th International Congress on Non-Motor Dysfunction in Parkinson's Disease and Related Disorders, would like to express its gratitude and acknowledge the following companies and organizations for their generous support of the Meeting:

PLATINUM SUPPORTERS

SILVER SUPPORTER

SUPPORTERs

81

Industry Organised Symposia Friday, December 5, 2014 10:30-12:00 Athena The role of dopaminergic and non-dopaminergic systems in mid- to late stage PD: New opportunities for dual intervention Symposium Organised by: Zambon SpA Chair: Paolo Barone (Italy) Chair: Jaime Kulisevsky (Spain) 10:40

VIDEO PRESENTATION OF ADVANCED PD Angelo Antonini (Italy)

11:10

TARGETING NON DOPAMINERGIC PATHWAY AS AN ALTERNATIVE APPROACH IN PD Susan Fox (Canada)

11:30

RATIONAL TREATMENT APPROACHES IN PD – ALIGNING MECHANISMS OF ACTION WITH MECHANISMS OF DISEASE AND PROGRESSION Heinz Reichmann (Germany)

Friday, December 5, 2014 13:00-14:30 Athena EXTENDING OUR UNDERSTANDING OF THE DOPAMINERGIC BASIS OF NON-MOTOR SYMPTOMS IN PD Symposium Organised by: Britannia Pharmaceuticals Chair: Amos Korczyn (Israel) 13:00 INTRODUCTION Amos Korczyn (Israel)

82

13:05

NON-MOTOR SYMPTOMS IN PD – IMPACT, RECOGNITION AND MANAGEMENT K. Ray Chaudhuri (United Kingdom)

13:25

PROGRESS IN NEUROIMAGING IN PD – INSIGHTS INTO THE ROLE OF DOPAMINE David J. Brooks (United Kingdom)

13:45

COGNITIVE DECLINE IN PD – RESEARCH DEVELOPMENTS Teus Van Laar (Netherlands)

14:05

SUMMARY AND QUESTIONS Amos Korczyn (Israel)

Saturday, December 6, 2014 Remote Objective Measurement of Parkinson’s

10:30-12:00 Athena

Symposium Organised by: Global Kinetics Corporation Chair: Heinz Reichmann (Germany) 10:30 INTRODUCTION Heinz Reichmann (Germany) 10:35

FLUCTUATION SCORES Malcolm Horne (Australia)

10:55 SLEEP K. Ray Chaudhuri (United Kingdom) 11:10

IMPULSE CONTROL DISORDERS Andrew Evans (Australia)

11:25

OBJECTIVE MEASUREMENT Filip Bergquist (Sweden)

11:40

SUMMARY & THOUGHTS ON THE SOCIETAL PERSPECTIVE OF SYMPTOM MEASUREMENT Angelo Antonini (Italy)

83

LIST OF EXHIBITORS Exhibitor Boston Scientific International

1

Britannia Pharmaceuticals

8

CANE SpA

3

Global Kinetics Corporation

5

IOS Press BV

11

Zambon SpA

2

St. Jude Medical

7

EXHIBITORS

84

Booth No.

EXHIBITOR AND SUPPORTER PROFILES ACADIA Pharmaceuticals Inc.

11085 Torreyana Road, Suite 100 San Diego, CA 92121, U.S. www.acadia-pharm.com ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related CNS disorders. ACADIA has a pipeline of product candidates led by NUPLAZID™ (pimavanserin), for which it has reported positive Phase III trial results in Parkinson’s disease psychosis and which has the potential to be the first drug approved in the U.S. for this disorder. Pimavanserin is also in Phase II development for Alzheimer’s disease psychosis and has successfully completed a Phase II trial in schizophrenia. ACADIA also has collaborative clinical-stage programs for chronic pain and glaucoma.

Boston Scientific International

2 rue René Caudron 78960 Voisins Le Bretonneux France www.bostonscientific.com Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.

Britannia Pharmaceuticals

100 Berkshire Place, Wharfedale Road, Winnersh, RG41 5RD Tel: +44 (0) 1189 215922 Email: [email protected] www.britannia-pharm.co.uk Britannia Pharmaceuticals Limited is a UK based pharmaceutical company specializing in niche innovative products for chronic and serious medical conditions, and in particular, the treatment of patients with Parkinson’s disease. The need for apomorphine as a treatment option for Parkinson’s disease has led to the development of APO-go and other associated brands around the globe, which are available in many countries through our Distribution or Licensing Partners.

85

EXHIBITOR AND SUPPORTER PROFILES (cont.) CANE' S.p.A.

Via Cuorgné 42/a I-10098 RIVOLI (TO) Italy www.canespa.it Canè was founded in 1978 as a manufacturer of ambulatory infusion pumps. Over the last 35 years it has grown to become the leader in the segment addressing the delivery of drug volumes ranging from 10-50 ml. The Crono series of ambulatory infusion pumps addresses four main therapeutic areas: Primary Immunodeficiency, Parkinson's Disease, Thalassaemia and pain control. In addition we have models dedicated to pulmonary hypertension and fertility treatment. Syringes may have volumes of 10, 20, 30 or 50 ml and infusions may be subcutaneous, intravenous or epidural depending upon the pump model. Canè works with pharmaceutical companies and other medical device manufacturers to provide customised solutions where required.

Club Mouvements Anormaux (CMA) /French movement disorders society

Rue Sainte-Marie 38 B/4000 Liège Belgium http://www.cma.neurosc.be Fondé en 1986, le Club des Mouvements Anormaux (CMA) regroupe des spécialistes des neurosciences provenant des pays francophones: France, Belgique, Québec, pays africains et asiatiques d’expression française. Son objet, tel que défini dans les statuts (ASBL, Loi 1901), consiste en l’étude clinique, physiologique et thérapeutique des mouvements anormaux, ses travaux concernent tout ce qui concourt à l’enseignement des mouvements anormaux et notamment dans le domaine de la formation continue. Objectives: Clinical, physiopathological and therapeutical studies of movement disorders.

Ever Neuro Pharma GmbH

Oberburgau 3 4866 Unterach Austria www.everpharma.com EVER Neuro Pharma is an Austrian pharmaceutical company focused on the field of neuroscience. Based on our experience and proprietary R&D technology platform we develop innovative therapies for neurological disorders. Among other agents our product portfolio is strengthened with Dacepton® (apomorphine hydrochloride) for the treatment of disabling motor symptoms in the advanced stage of Parkinson´s disease. We focus on the complete Package of Care including Medical Devices for the continuous drug delivery. The future development of therapies for neurological diseases will increasingly rely on the pleiotropic, multifunctional approach. Recognizing this trend we keep to our endeavor for further refinement of the neurotrophic therapies, and for constant improvement of our patient oriented services. 86

Global Kinetics Corporation

Lvl 6, 530 Collins Street Melbourne, 3000 Australia www.globalkineticscorporation.com Global Kinetics Corporation (GKC) along with the Florey Neuroscience Institute has developed the Parkinson’s KinetiGraph (PKG) for objective, ambulatory assessment of bradykinesia and dysregulation in Parkinson’s disease. The PKG records a patient’s movement continuously over 10 days (providing PD medication reminders as prescribed) and reports correlations of fluctuation severity with respect to dosage. The PKG report provides clinicians with an assessment of a patient’s clinical state which is objective, includes scaled measures of bradykinesia and dysregulation with repeat reliability, links fluctuations with the timing of medication, is comparable over time and allows assessment during the activities of daily living.

IOS Press

Nieuwe Hemweg 6B 1013 BG Amsterdam The Netherlands www.iospress.com IOS Press (www.iospress.com), established in 1987, publishes around 100 international journals and approximately 90 book titles a year, in a broad range of subjects. IOS Press has a strong neurosciences package, with one of the top journals being the Journal of Alzheimer’s Disease (Impact Factor 3.612, according to JCR 2013). JAD has three sister journals: Journal of Parkinson’s Disease (www.journalofparkinsonsdisease.com), Journal of Huntington’s Disease (www. iospress.com/journal-of-huntingtons-disease) and Journal of Neuromuscular Diseases (www.iospress.com/journal-ofneuromuscular-diseases). Visit IOS Press at booth #11.

Medtronic

Rte du Molliau 31 1131 Tolochenaz, Switzerland www.medtronic.com At Medtronic, we’re committed to Innovating for life by pushing the boundaries of medical technology and changing the way the world treats chronic disease. Last fiscal year, more than ten million patients benefited from our products and therapies. Medtronic DBS Therapy has been used in more than 120,000 patients worldwide for the treatment of Parkinson’s disease, essential tremor and dystonia.

87

EXHIBITOR AND SUPPORTER PROFILES (cont.) Merz Pharmaceuticals GmbH

Eckenheimer Landstrasse 100, D-60318 Frankfurt am Main, Germany. Phone: +49 (0)69 1503 0 Fax: +49 (0)69 1503 722 Email: [email protected] Website: www.merz.com Merz Pharmaceuticals is a research-based pharmaceutical company, headquartered in Frankfurt, Germany, with key competences in neuroreceptor biology. Merz has developed meantime (marketed under the brand names Axura® & Akatinol®) the first drug available for moderate to severe Alzheimer’s disease. Xeomin®, a botulinum toxin A free from complexing proteins (incobotulinumtoxin A), is manufactured using a unique US-FDA approved state-of-the-art biotechnological process according to the highest international GMP requirements and is registered in > 20 countries for various indications including blepharospasm, cervical dystonia and post stroke spasticity

Mundipharma Research GmbH & Co. KGHöhenstraSe 10

65549 Limburg, (Lahn) Germany www.mundipharma-rd.eu Mundipharma Research is a young, dynamic organisation wholly dedicated to the research and development of highly effective and innovative medications. Based in Europe (in Cambridge, England, and Limburg, Germany), we work on behalf of our independent associated companies and in collaboration with pharmaceutical companies to bring medications to an international market.

St. Jude Medical Coordination Center BVBA

The Corporate Village Da Vincilaan 11 Box F1 1935 Zaventem Belgium sjm.com What if a company could invent breakthrough technologies that transform the treatment of some of the world’s most expensive epidemic diseases? At St. Jude Medical we are turning what if into why not by partnering with physicians, hospitals and insurers to save and improve millions of lives worldwide – while reducing health care costs for all. As a true leader, St. Jude Medical is committed to meeting or exceeding the high quality and safety expectations of our patients, customers and regulators. Quality is the shared belief that unites all 16,000 of our employees – it is built into everything we do and is the guiding principle behind every product we create.

88

Zambon SpA

Via Lillo del Duca, 10 20091 Bresso (MI) – ITALY Zambon is a leading Italian pharmaceutical and fine-chemical family company, well-established in 3 therapeutic areas: respiratory, pain, woman care. The Group is strongly working on the treatment of the chronic respiratory diseases as COPD and asthma and on CNS area with a molecule for Parkinson disease.

Wisepress Medical Bookshop 25 High Path, Merton Abbey London, SW19 2JL UK www.wisepress.com Wisepress.com, Europe’s leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver worldwide. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers.

89

Make Measurable Change to Parkinson’s Please visit our stand at NMDPD 2014 to learn more

www.globalkineticscorporation.com 90

VERCISE

™

Deep Brain Stimulation System

Now for Parkinson’s disease and Dystonia The first and only DBS system with current steering* designed for precise neural targeting to customize therapy for your patients. 25 Year Battery Life1

*Multiple Independent Current Control: 16 independent current sources engineered for fine adjustment of stimulation position and shape. 1) Boston Scientific Physician Manual The Vercise™ Deep Brain Stimulation (DBS) System is indicated for use in unilateral or bilateral stimulation of the subthalamic nucleus (STN) or internal globus pallidus (GPi) for treatment of levodopa-responsive Parkinson‘s disease which is not adequately controlled with medication and also for treatment of intractable primary and secondary dystonia, for persons 7 years of age or older. All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Information for the use only in countries with applicable health authority product registrations. NM-233706-AA_APR2014 © 2014 Boston Scientific Corporation or its affiliates. All rights reserved.

www.bostonscientific-international.com

Notes

Notes

94

95

Notes

96

program at a glance

Saturday, December 6, 2014 Time 07:3008:30 08:3010:00 10:0010:30

Thursday, December 4, 2014 Time 15:00-16:30 16:30-17:00 17:00-19:00 19:00

Athena Auditorium

Hermes Auditorium CMA session

Opening Ceremony Plenary Session 1 Networking Reception

10:3012:00 12:0013:00

Friday, December 5, 2014 Athena Auditorium

Hermes Auditorium

07:0008:30

Inaugural Trainees symposium 1

Inaugural Trainees symposium 2

08:3510:00

Plenary Session 2

10:0010:30

Coffee Break, Exhibition and e-posters viewing e-Poster Presentations: NMS - Non motor symptoms Sponsored symposium Not included in the CME/CPD program

Time

10:3012:00

Risso 6 7:30-8:50 Free communication: Non motor symptoms

12:0013:00

Break, Exhibition and e-posters viewing

13:0014:30

Sponsored symposium Not included in the CME/CPD program

14:3516:00 16:0016:30 16:3018:00

MSA

Non Pharmacological Treatment

Risso 7 7:30-8:30 Free communication: Miscellaneous

13:0014:30

14:3516:00

16:0016:30 16:3018:15

Coffee Break, Exhibition and e-posters viewing e-poster Presentations: QoL - Quality of life Sleep problems Frontotemporal and the sleep dementia structure at Olfaction Parkinsonism different stages of PD

Plenary Session

DBS and non-motor symptoms of PD Biomarkers Integrating in PD and 5HT and DA related Impulse Control Sleep functions in disorders – Disorders Basal Gangliaare we there Fundamentals yet? Coffee Break, Exhibition and e-posters viewing e-poster Presentations: Cognitive Dysfunction 1 Plenary Session 5 Basal Ganglia and Emotion

Animal models of PD

Non motor aspects of Dystonia

Free communication: Cognitive dysfunction in PD

DBS Deep brain stimulation

Parallel Session

Athena Auditorium

Hermes Auditorium

Risso 6

07:3009:00

Contribution of nuclear Gastrointestinal Neuropathology medicine to aspects in PD PD, PDD and DLB

09:0510:30

Pain in PD

10:3011:00 11:0012:30 12:3013:00

CMA Session

Break, Exhibition and e-Poster viewing

Sunday, December 7, 2014 Time

Genetics of non motor symptoms in PD

Athena Hermes Risso 6 Risso 7 Auditorium Auditorium Plenary Session 3 Plenary Session 4 Coffee Break, Exhibition and e-posters viewing e-poster Presentations: Deep Brain stimulation; depression Sponsored symposium Not included in the CME/CPD program

Oral Presentations

Neuroimaging of non-motor deficits in PD

Vascular Factors in PD

Risso 7 The spectrum of sexual disorders in PD: from hypo- to hypersexuality Detection of neuropsychological deficits in PD – scales and biomarkers

Coffee Break, Exhibition and e-posters viewing e-poster Presentations: Cognitive Dysfunction 2 Plenary Session 6 Congress Closing Ceremony Trainees Symposium

Industry Sessions

Social Event

final program

final program

Suggest Documents

Final Program

final program

Final Program

final program

Final Program

final program

FINAL PROGRAM

final program

Final Program

Final Program

Final Program

Final Program

final program

final program

final program

Final Program

Download Final Program

Final Technical Program

final program - saric.us

final program

final program

Final Program - IFS2018

final program

FINAL PROGRAM - miccai 2013